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Abstract 
The synthesis of IH1, a peptide designed to mimic a discontinuous epitope on HIV-I 
gp120, is reported. The aspartiniide rearrangement inherent in this sequence, and in 
the peptide GC1, has been studied and reduced to low levels. The syntheses of 
variants of peptide GC1, containing differing number of residues found to be 
important for CD4 binding, have also been achieved. Thus peptides containing one, 
two, three and four residues necessary for high affinity binding have been synthesised. 
In addition a peptide has been synthesised which incorporates a synthetic 0 turn 
moiety other than the Cys-Val-Cys bridge present in GC1. Polyclonal sera raised to 
these peptides and their CD4 binding properties have been investigated. 
1111, the peptide containing four residues responsible for high affinity binding to CD4, 
has also been shown to interact with receptors on the surface of CD4 cells. This non-
CD4 recognition has been investigated utilising a photolabelled chemokine, MIP-la. 
Results indicate that this binding involves interaction with CC-CKR5, a MEP-la 
binding site thought to be involved in HIV-cell fusion. 
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Chapter 1 : Introduction 
1.1 The immune response 
This project has been designed to obtain information which could be used towards the 
formation of a vaccine against AIDS. The work uses the humoral immune response to 
raise antibodies which will cross react with the virus coat protein. A bnef introduction 
to the immune system is given below. 
Protection against microbes in the body are afforded by two systems, natural and 
acquired immunity. 
Natural immunity : includes physical barriers, phagocytic cells and various 
blood-borne molecules used in defence. These are present in the body before 
infection and are not specific for individual invaders. 
Specific or acquired immunity: consists of defence mechanisms induced or 
stimulated by exposure to a foreign substance, or antigen. Acquired immunity 
is specific to a particular antigen, with the specific immune system 
'remembering' each encounter so subsequent exposures stimulate increasingly 
efficient effector systems. Acquired immunity also amplifies the protective 
mechanisms of natural immunity, focusing them to sites of antigen entry, 
leading to faster elimination of the antigen. Features of natural and specific 
immunity are shown in Figure 1.1 below. 
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Specific immunity itself can be broken down into two different systems classed as 
humoral and cell-mediated immunity. 
Hunioral immunity: mediated by circulating proteins produced by B 
lymphocytes, termed antibodies or immunoglobulins, responsible for specific 
recognition and elimination ofextracellular antigens. 
Cell-mediated immunity: mediated by T lymphocytes and is effective 
against intracellular antigens. 
Natural Specific (Acquired) 
Physiochemical barriers Skin, mucous membrane, Cutaneous 	and 	mucosal 
enzymes 	in 	mucosal immune systems; antibody 
secretions. in mucosal secretions. 
Circulating molecules Complement, cytokines. Antibodies, cytokines. 
Cells. Phagocytes (macrophages, Lymphocytes. 
neutrophils), natural killer 
cells 
Figure 1.1 
Features of natural and specific immunity 
This project was designed to generate antibodies raised against synthetic peptides 
which were able to cross-react with HIV. These peptides were chosen to mimic 
regions of the outer coat protein of H1V, which are important in the lifecycle of the 
virus. 
2 
The processing of a foreign antigen in the initiation of a humoral immune response 




ci{ 	 T helper 01 10 	 cell 
Virion 
/ 
11-2 release from I helper 
cell-self stimulation 
leading to proliferation 
and differentiation of T helper cell 
Cytokine production 
Macrophage 	Inflammation 	Differentiation 	Formation of 






B cell with 
attached virion Memory 
B cell 
Figure 1.2 
The humoral immune response 
'1 
The initiation of a humoral immune response includes the following steps: 
An antigen presenting cell (includes macrophages and dendritic 
cells) ingesting an invading antigen. 
The antigen, in the above case a virion, is rapidly internalised via 
phagocytosis. 
Internal enzymatic degradation breaks down the proteins of the 
virion into smaller peptides within the iysosomal compartment of the cell. 
Peptides bound to specialised proteins called the Major Histocompatibility 
Complex class 2 (MHC-U). 
d) The MHC-ll / peptide complex is displayed on the surface of the cell. 
When the T-cell receptor recognises the displayed peptide, it binds to the 
antigenic peptide with a surface receptor ,CD4, also binding to the MHC-11. 
interleukin-2 (11-2), a T cell growth factor, is released, stimulating the I 
helper cells with bound antigen and resulting in proliferation and 
differentiation of the T helper cells. 
T helper cells produce other cytokines allowing co-ordination of the 
bodies defences including inflammation at the site of infection, macrophage 
activation and increase of cytotoxic T lymphocytes in the area of infection. 
The work in this thesis is concerned with the response of B lymphocytes to activation. 
Upon stimulation, the B lymphocytes are affected in one of two ways, either maturing 
to plasma cells or going on to form memory B lymphocytes. The plasma cells produce 
the antibodies necessary for efficient foreign body clearance. The only B lymphocytes 
affected are those with bound antigens to their surface receptors. These receptors 
have the same specificity as do the antibodies produced, hence bound antigen 
indicates the ability of the antibodies to bind to the foreign antigen. B and T 
lymphocyte memory cells produced in the humoral response are long lived cells which 
are easily stimulated to form plasma cells in the case of B lymphocytes, and cytokines 
in the case of T lymphocytes. These memory cells are the basis of the ability of the 
body to mount an improved response upon subsequent encounter with the same 
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antigen. B cell stimulation and changes in cytokine profile during the response leads to 
mimunoglobuiin class switching by the B lymphocytes. Secondary challenge with the 
same antigen then gives an enhanced response, with greater production of IgG 
relative to 1gM. This ability to 'learn' from past challenges produces an antibody titre 
as shown in Figure 1.3. 
A 	 Antigen A 	 Anti-A 
+ 	 Anti-B 









A normal immune response to antigen A 
In the past, there has been a tendency to use whole inactivated or live attenuated virus 
as a vaccine. These are likely to be very similar to the native virus, and hence the 
antibodies raised react with the pathogen. The use of either of these methods with 
HIV leads to grave concerns over safety as it is extremely difficult to ascertain 
whether all viral particles have been inactivated or attenuated. Live attenuated viruses 
are also difficult to use due to the variability of the virus. This leads to the chance that 
an attenuated virus could mutate back to a virulent form. The envelope glycoprotein 
of HIV, gp 120, is extremely variable and mutates readily. Most of the neutralising 
antibodies are raised to gp 1201,  hence vaccines using one isolate would be unlikely to 
cover sufficient of the viral population to lead to eradication. 
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1.1.1 Synthetic peptides as antigens 
As stated earlier, gp 120 is the surface protein to which most neutralising antibodies 
are raised. It has been shown that the actual major neutralising determinant in human 
infection is part of gp 120 called the V3 10op 2 '3 '4. The high variability of this region 
leads to type specific antibodies, antibodies capable of neutralisation only one specific 
viral isolate. Antibodies raised to this area have also been shown to enhance 
infection5 '6 . 
Due to these problems, there is now a move towards the use of areas of the virus 
capable of neutralisation. Thus, parts of viral proteins can be introduced as peptides, 
allowing the priming of the immune system without the danger inherent in the use of 
viral particles. Also, areas found to be variable or capable of raising enhancing 
antibodies can be omitted. There are precedents for the use of peptides to raise 
antibodies capable of neutralising viruses, as discussed below. 
Much work has been attempted on the use of synthetic peptides as antigens for the 
use in a new generation of synthetic peptide vaccines 7. Available information on the 
position of antigenic sites in toxins, viruses and parasites has stimulated the research 8,9 
and protective immunity has been elicited against foot and mouth 1,12 
influenza ' 3"4, hepatitis B' 5"6"7 and cholera by immunisation with synthetic peptides. 
The idea is that these synthetic peptides mimic sites important in the lifecycle of the 
virus in order that antibodies raised will not only flag virions for destruction, but could 
also block these important areas. Unfortunately this is not easy, with the sequence 
utilised needing to be chosen carefully. Linear peptides are rarely able to mimic 
desired sites on folded proteins to any great extent, as will be discussed below. 
1.1.2 Epitopes 
Epitopes are those parts of the antigen which are bound, or 'recognised', by the I or 
B antigen receptor. Thus, an epitope is a set of amino acids which bind to the antigen 
binding site of these antigen receptors. T lymphocyte epitopes differ from B 
lymphocyte epitopes in both amino acid sequence and length. T lymphocyte epitopes 
tend to be linear consisting of 11-23 amino acids. They need not lie on the urface of 
the molecule. B lymphocyte epitopes tend to be discontinuous and shorter than the T 
lymphocyte epitope, and are usually found on the surface of the molecule. 
Epitopes can be split into two different classes, continuous and discontinuous areas 
of a particular protein. 
Continuous Epitopes: These are epitopes defined by a stretch of amino 
acids in direct peptide linkage with distinctive conformational features 
allowing the binding of a specific antibody. 
Discontinuous Epitopes: These consist of a group of amino acids which are 
not in direct peptide linkage but, as a consequence of the folding and three-
dimensional structure of the protein, they are close enough in space to allow 
the binding of a specific antibody. 
Most of the work up to now has concentrated on the synthesis of linear peptides to 
mimic continuous epitopes. However, it is well known that most of the epitopes on 
any native protein will be discontinuous to a certain extent 18 . Thus, the use of linear 
peptides does not necessarily give antibodies capable of cross reacting with the native 
molecule, even if parts of the linear sequence of the protein are used. 
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1.1.3 Choice of sequence 
The classical way of obtaining information on important parts of the viral protein of 
interest is the use of linear peptides to map the epitope of antibodies raised to the 
native protein. Peptides used to map the surface of proteins have been widely used", 
giving information on areas accessible to the immune system. From this work, a 
picture can be built up as to the important parts of the protein. The removal of whole 
domains of the protein can give ideas of the important areas in the molecule, but it is 
sometimes difficult to tell whether these removed domains are acting as scaffolding or 
have biological importance themselves. Point mutation studies, where certain amino 
acids are removed or replaced 20, can also give an idea of important sections, or even 
information on widely dispersed areas acting together 2 ' and affect overall folding to a 
much smaller extent. Point mutation studies are also more likely to give information 
on discontinuous areas. 
Structural information can be derived in a variety of ways including biological 
methods described above. Much information can be obtained from computer 
simulations of the peptide 22 ' 23. This technique uses physical information from the 
peptide, and information from other known and related structures, to give an 
approximation of the protein structure. Unfortunately, due to the enormous amount of 
interactions in a folded protein, these results tend not to be very accurate. NMR 
studies24 also can be used to give structural information, along with crystallographic 
procedures. Both of these are extremely powerful tools, but are not suitable for all 
proteins. 
Although relatively difficult, it is possible to predict the areas essential for either 
binding or post binding events. Peptides can then be designed to mimic this area. It is 
unlikely that a linear peptide will obtain the correct structure in solution in order to 
mimic the native protein. However, this may not be a problem providing sufficient 
similarity exists. There is evidence that the actual process of binding induces structure 
in the peptide. Thus, it may be that the peptide need only resemble the native protein 
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and contain some flexibility to give the required shape. The following work uses this 
premise, a linear peptide has been designed but a turn introduced to give structure. 
This turn also allows the peptide to present discontinuous epitopes, as will be 
discussed later. 
The use of synthetic organic compounds as scaffolding for peptides has become 
another useful way to mimic native proteins. This can allow different areas of the 
protein to be bound together as they would in the folded protein. It also allows T cell 
epitopes from the protein to be included with B cell epitopes increasing the huinoral 
response. The areas of interest include multiple antigenic peptides (MAP) 25, which 
have been used in the formation of B cell and T cell containing systems 26 '27 '28 . The 
template assembled synthetic protein (TASP) 29 can be used in the same way to design 
protein structure 30 '3132 . Kemp's Triacid has also been used in similar ways 33'34. 
1.2 Human Immunodeficiency Virus (HIV) 
In 1981, young homosexual men in the United States were presenting to doctors with 
diseases linked to immune suppression 35 . It soon became clear that this syndrome was 
due to a virus. A few years after the initial recognition of this new disease state, 
isolation and characterisation of the virus was achieved, and H1V was proven to be 
the etiological agent of Acquired Immunodeficiency Syndrome, AIDS 36 ' 3738 .%The virus 
was identified as a member of the lentivirus family and as such, a retrovirus. Unlike 
other members of the lentivirus family, which affect T cells by immortalising them into 
continuous growth, one of the major pointers for Hill infection is the reduction in the 
number of I cells present in the body over time 39 ' 40 . 
1.2.1 HIV pathogenesis 
Hill infection is highly variable between individuals 41 ' 42 but, generally events 





Acute 	Asymptomatic 	ARC 	AIDS 
Infection Carrier 
Time after HIV infection 
Figure 1.4 
Features of }{IV infection (from reference 60) showing 
ARC (Aids related complex), (1) CD4 cell count and (2) Viremia 
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Prior to seroconversion, when the body initiates production of antibodies against the 
virion, high levels of virus can be detected in the blood. Viremia is then reduced to a 
low level, where it generally stays, apart for episodic release of varying amounts of 
virus over time. It is thought that this suppression of the virus could be mediated by 
antiviral CD8 cells43 '. At the same time as clinical symptoms become apparent, 
viremia rises to a high level, where it stays throughout the final period of disease. Also 
at this time, the CD8 anti-HTV response begins to decrease. 
The CD4 cell number decreases sharply during primary infection before rising to a 
level which is still below normal. A slow decrease in cell count then occurs 
throughout the asymptomatic state. This is thought to be due to destruction of cells 
by apoptosis45 (see later). Once symptoms occur, a marked decrease in CD4' count 
can be seen at the same time as the increase in viremia. 
1.2.2 HIV structure 
Two closely related types of the virus have been identified, designated IIIV- 1 and 
HIV-2. They have 40% homology in their surface proteins and cause indistinguishable 
clinical syiidromes46. Like all viruses, HIIV has two distinct stages in its lifecycle, the 
intra- and extracellular stage. A single virus particle, or virion, of lily has a structure 
as shown below (Figure 1.5). 
11 






The FIIV virion 
The virion has no biochemical pathways, the virus entering a host cell and subverting 
the cellular biochemistry in order to replicate. HIV is a retrovirus, hence the genetic 
information is carried as RNA, in this case two identical strands, each 9.2-9.7 
kilobases long enclosed by the subunits of the p24 protein in the central cap sid. The 
genetic material of }IIV consists of env, encoding for the envelope glycoproteins, gag, 
for the structural core proteins, poi for the viral protease enzymes, and also vpr, tat, 
rev, nef and vpu whose products regulate viral reproduction. 
Also present in the capsid is reverse transcriptase, the enzyme which transcribes the 
viral RNA into DNA before insertion into the host DNA. The whole virion is 
surrounded by a lipid bilayer. The envelope glycoprotein has two components gp 120 
and gp4 1 and these project out of the lipid bilayer. It is these that interact with the 
host cell prior to insertion of the genetic material. The envelope glycoproteins are 
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synthesised in the host cell as a precursor protein, gp 160, which is proteolytically 
cleaved by a host-cell protease into gpl2O and gp41 47 ' 48. These two glycoproteins are 
then held together by non-covalent interactions' 9 . 
1.2.3 Insertion and replication of the virion 
Viral insertion and replication can be visualised as in Figure 1.6 below. The initial 
stage of insertion into the host cell is high affinity binding of gp 120 to the host cellular 
receptor CD4 49 '50 '51 '52 CD4 is not internalised 53, rather, structural changes occur to 
the gp 120545556 which allow presentation of gp4 1. Entry into the cell is pH 
independent57 ' 58, indicating that IIIV fuses directly with the cell surface membrane. 
Insertion of the hydrophobic amino-terminus of gp4 1 into the cell membrane initiates 
fusion of the virus envelope with the cell surface membrane. The virion then uncloaks 
and enters the cell. Upon entry, reverse transcriptase is used to transcribe the viral 
RNA to DNA. This DNA is then circularised and inserted randomly into the host 
DNA by the viral integrase. The integrated DNA copy of the viral RNA genome is 
known as the provirus. Insertion of the viral genetic material can have several 
consequences. The cell can die from the presence of foreign DNA affecting the 
cellular pathways. The virus could he dormant, with insertion of viral DNA not 
leading to replication, or the infected cell could go on to produce viral particles. The 
production of these particles from the integrated HIV provirus occurs only upon 
activation of the infected T lymphocyte. The host biochemistry is subverted, allowing 
the formation of viral RNA and RNA coding for viral proteins. Once formed, the 
proteins are enzymatically cleaved and the virion forms inside the cell. The formed 
virion moves to the surface of the cell where it buds, taking with it some of the host 





Virion insertion and replication in a host cell: 1) binding of gp 120 to CD4, 2) 
uncoating, 3) reverse transcription, 4) circularization, 5) integration, 6) transcription, 
7) translation, 8) core particle assembly, 9) final assembly and budding 
(from reference 60) 
1.2.4 Cytopathic effects of viral replication on host 
As previously described, isolates of HIV recovered from the individual in advanced 
disease has a greater capacity for killing infected cells than strains isolated in the 
clinically latent period. These cytopathic effects of the virus on the host are many and 
varied. A major biological feature of HIV infection is the formation of muitmucleated 
cells from the fusion of infected cells with uninfected CD4 cells. This effect is termed 
syncytia formation and has been shown to involve the envelope glycoproteins 59 . Cells 
are seen to degenerate due to the presence of the virus affecting the permeability and 
integrity of the cellular membrane. Cytopathology can also be associated with the 
accumulation of viral DNA in the cytoplasm of the cell. The possible mechanisms of 
cytotoxicity by HIV or its proteins are described below (reviewed in ref 60). 
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Postulated methods of viral cytotoxicity in H1V infection include: 
Syncytium formation. 
Accumulation of unintegrated viral DNA. 
Virus release causing changes in membrane integrity. 
Virus alteration of plasma membrane permeability to cations. 
Decrease in synthesis of membrane lipids. 
Decrease in "second messenger" (diacylglycerol) activity. 
Interference with cellular heteronuclear RNA processing. 
degradation of cellular mRNA and reduction in cellular protein synthesis. 
Induction of apoptosis (see below). 
Release of cytotoxic cytokines by infected cells and/or uninfected cells. 
Destruction by immunogenic responses. 
I) Competitive inhibition by IilV of normal growth factors. 
1.2.5 Apoptosis 
One of the difficulties in understanding the complex pathology of HIV infection is to 
explain the progressive depletion of CD4 helper T cell population and the consequent 
destruction of the immune system. The view that HIV causes AIDS only by directly 
killing C134 cells, for example by lysis, has been questioned by many workers in the 
field". Gougeon et a!62 noticed that peripheral blood lymphocytes from asymptomatic 
HIV-infected individuals are primed for apoptosis. Apoptosis is a form of 
programmed cell death and occurs through the activation of an intrinsic cell suicide 
mechanism (reviewed in ref 63). During apoptosis, the nucleus and the cytoplasm 
condense, and the dying cell often fragments into membrane-bound apoptotic bodies 
that are rapidly phagocytosed and digested by macrophages or neighbouring cells. 
Apoptosis can be mediated by the interaction of a cellular surface receptor, Fas, with 
its ligand64. Fas ligand65 is a membrane protein and a member of the tumour necrosis 
factor (TNF) family66. It has been shown in mice with mutated Fas or Fas ligand that 
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the Fas system plays an important role in destruction of autoreactive immune cells 67 
and as an effector molecule of cytotoxic T cells 68 . 
It was known that cross-linking of CD4 molecules with CD4 antibodies or with gpl2O 
led to upregulation of Fas 69. Also cross linking of the CD4 receptors with CD4 mAb's 
led to apoptosis, as long as Fas is present in a useable form 70. It was noted that if 
gp 120 was used to effect the cross-linking, the cell was primed for apopthsis 71 ' 72 . It 
has also been shown that Fas was upregulated on the surface of T cells in HIIV 
infected patients73, along with Fas ligand 74 and this was associated with apoptosis. 
From this and recent research by Silvestris et a!75 , it has been shown that Fas 
overexpression parallels the progression of disease in AIDS. This would indicate that 
apoptosis and in particular the Fas mediated pathway, play major role in the depletion 
of CD4 helper T cells. 
1.2.6 gp120 structure 
The numbering of gp 120 in this thesis refers to the BH1O clone of IIIV from Ratner et 
a!76 . 
It has been shown that gp 120 is a highly variable molecule which shows extensive 
genetic difference between isolates, and undergoes rapid evolution mainly due to the 
inefficient reverse transcription 77,78  and no ability to proof read the viral RNA in the 
cell. More highly conserved amino acids include the cysteines used to form the 
interchain disulfide bonds, which are extremely conserved 79 . gp 120 is highly 
glycosylated80, with about 50% of the mass of the molecule due to sugars. 
Glycosylation occurs at both N 81 ' 82 and 0 linked 113  glycosylation sites. The sites are 
not randomly distributed, but are also highly conserved. It has been found that 
glycosylation is unnecessary for CD4 binding or antibody recognition 84, although it 
must be present for correct folding 85 . 
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The amino acid sequence of gp 120 from many different viral isolates has been 
sequenced and comparisons of these sequences have shown the presence of five linear 
regions that are highly conserved 86 . The structure can be visualised as in Figure 1.7. 
Cl Vi 	V2 C2 	V3 	C3 	V4 C4 V5 C5 
30 	100 	 200 	 300 	 400 	 500 
Figure 1.7 
gp 120 showing areas of conserved and variable amino acids 
Due to the size of the molecule, and its extensive glycosylation, the structural data is 
limited. The known data can be summarised as in Figure 1.9. The data discussed 
above is the limit of current knowledge as to structure of gp 120. There have been 
attempts to model the structure 21,22  (see Figure 1.8) but their validity has not been 
confirmed by structural studies, such as X-ray crystallography or NMR. 















high mannose 	complex 
Figure 1.9 
Structure of gp 120 
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1.2.6.1 The CD4 binding site 
As with the overall structure of gp 120, the CD4 binding site on gpl2O is not clearly 
defined. Cordonnier et allowed that four conserved regions of gp 120 were needed 
for high affinity binding. It was found that an area of the C4 region was needed for 
binding, and that mAb's blocking CD4 interaction recognise epitopes in this region 88 . 
Thus at the time this was thought to be the binding site. However, severak mutation 
studies89 '90 have shown that amino acids essential for correct binding of CD4 are 
spread throughout the conserved regions of gp 120. Due to this, the binding site is 
thought to be discontinuous, with many areas of gp 120 being involved. There is a 
maximum binding region, however, with a large part of the N terminus, some of the C 
terminus, and the variable regions Vi, V2 and V3 found unnecessary for binding 91 . 
The mutation studies mentioned above have shown that there are five amino acids 
which play a large part in the high affinity binding of CD4. These are Thr-257 in the 
C2 region, Asp-368 and Glu-370 in the C3 region and Trp-427 and Asp-457 in the C4 
region 71 . These amino acids are absolutely conserved in all HIV- 1 isolates. The amino 
acids are marked in Figure 1.8. All five of these amino acids have been shown to fall 
within the epitope for a CD4 blocking antibody, 1.5e92, again suggesting they are 
close in space in the folded protein (see Figure 1.10). 






Antibody interaction with CD4 binding site 
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1.2.6.2 The V3 loop 
The amino acids of the V3 loop he within the disulfide bridge formed between two 
invariant cysteines at positions 303 and 338. As explained earlier, the V3 loop is the 
principal neutralising determinant, with over half of all antibodies produced 
recognising this one area. These antibodies are extremely potent neutralising agents, 
but are also very type specific 5. Most antibodies raised early in the disease rend to be 
against the V3 loop. The neutralising antibodies do not prevent gp 120 binding to 
CD4, rather they block an unknown post-binding event 93 . The V3 loop is highly 
variable, and increases in variability during progression of the disease 94 . Progression 
also leads to the emergence of virus variants which resist neutralisation 95 '96. Despite 
the high variability, the tip of the V3 loop has been shown to be relatively conserved, 
with the GPGR motif being extremely conserved 97 . This area seems to be involved in 
some post binding event as mutations in the tip greatly reduce viral fusion 98. Clements 
et a199 have shown the presence of potential proteolytic cleavage sites very near the 
tip of the loop. Research has shown the cleavage of the V3 loop with soluble 
CD4 100and with thrombin' ° '. Purified Trypstatin, a serine protease inhibitor, reduces 
syncytium formation 102 . Also Tryptase TL2, a serine esterase from CD4 cells, was 
strongly inhibited with gp 120'° . It was later shown by peptide studies that the V3 
loop blocks the protease action' 64"05 , indicating the V3 loop has the ability to act as a 
ligand for a cellular bound protease. 
1.2.6.3 Viral Tropism 
The V3 loop also has a great effect in the tropism of a particular viral strain. It has 
been shown to be the primary determinant of viral tropism' 06"07 . Indeed, a single 
amino acid difference Asp-323 to Lys, leads to a change from M-tropism to T-
tropism108. Zhu et a!' 09 have shown that the viral phenotype at initial seroconversion 
was found to be uniformly macrophage tropic and non-syncytium-inducing. As 
disease progresses, an increased replicative capacity of the virus occurs in peripheral 
blood mononuclear cells (PBMC's) and T lymphocytes" ° . Rapidly replicating variants 
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thus emerge during the asymptomatic period, and this appearance tends to indicate a 
worsening of the condition of the patient. Antibody studies tend to suggest two 
distinct conformations for the V3 loop, and these conformations elicit viral tropism"'. 
Gu et al"' have shown that the cleavage sites in the V3 loop, discussed above, also 
have an effect on viral tropism. 
1.2.6.4 gplZO interaction with gp4l 
As stated earlier, the envelope glycoproteins gpl20 and gp4l are formed as a 
precursor peptide gp 160. This is processed in the cell to form the two proteins. The 
transmembrane protein, gp4l, plays a key role in both virus-mediated cell-cell fusion 
and interaction by cell free VirUS113,114.  The N terminus of gp4 1 has been found to act 
as the fusogenic domain, whose function probably involves insertion into and 
disruption of the target cell membrane' 15  The N terminus has been shown to have a 
leucine zipper motif changes to which do not affect interaction with gp 120 but has a 
major effect on the virus Iifecycle" 6" Mutagenesis studies have shown that amino 
acids away from the N terminus, a sequence running from 696 to 707, and in 
particular basic residues at 696 and 707, play a crucial role in fusion' 18  The area 
running from 521-663 has been shown by antibody mapping to be covered during the 
non-covalent gpl2O-gp4l binding" 9. This is in agreement with data showing the areas 
involved in gp120 binding to be 528-562 and 608628120,  560-561 and 571582 121 , 
579-611 122  Interaction areas on gp 120 have been found to be in the conserved, 
hydrophobic, regions at the N and C terminus (Cl and C5)'23" 24. As with gpl2O, 
structural information is limited, but comparisons with other lentiviruses give a 
predicted structure as in Figure 1.11. 
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Figure 1.11 
Predicted structure for gp4 1 
(adapted from ref. 125) 
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1.2.6.5 The gp120 binding site on CD4 
The CD4 structure has been found to be made up of four domains as in Figure 1. 12a 
below. 

















Overall structure of CD4 suggested from the amino acidquence 
The binding site for H1V was initially found to be located somewhere on domain 1 of 
CD4 126"27 . It was subsequently found that the binding site was discontinuous 12" 
containing regions from CDR2 129"30 and CDR3 131 ' 132 Mutation studies have shown 
there are several amino acids implicated in the high affinity binding, with Phe-43 and 
Arg-59 likely to contact gp l2O'. Lys-35 and Lys-46 are also thought likely to 
contribute to binding 134  (see Figure 1.12b, below). Research has also implicated 
domain 2 in post binding events, perhaps interfering with conformational changes in 
gp 120/gp4l or CD4 that are necessary for fusion 135 . 
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Figure 1.12b 
Domain 1 of CD4 showing residues involved in gpl2O binding 
1.2.6.6 The C2 region and non-CD4 entry 
Although it is clear that CD4 is the principal cellular receptor for MV, many cell lines 
of the nervous system do not express CD4, but can be infected. This infection is less 
efficient than through CD4, but it is possible with several strains. Fantirn et al' 36 
showed the level of galactosyl ceramide, expressed on the surface of particular cells, 
is associated with permissiveness to HIV infection. Harouse et a1137 showed that 
antibodies against galactosyl ceramide inhibit uptake and infection of two neural cell 
lines. The area of gp 120 capable of interaction with this cellular receptor has been 
mapped to the C2 region, between amino acids 206275 138 
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1.2.7 Co-receptors in HIV infection 
As described earlier, CD4 cells are the major target for HIV replication (for a review, 
see ref 139). However it was clear that productive infection required more than the 
presence of CD4 on the cellular surface. 
Expression of CD4 on the cell surface does not necessarily lead to membrane 
fusion 140.  Indeed, I-IIV strains are generally classified as T-cell tropic (T-tropic) or 
macrophage tropic (M-tropic) depending upon their differing ability to infect CD4 
target cells. It has been known for many years that the presence of the CD4 receptor 
on the surface of a murine cell leads to the ability to bind the virus, but not fusion and 
internalisation 52. Recent work 14 ' has shown that the block to fusion, and hence 
infection, of a murine cell line is not due to the presence of an inhibitory component 
on the murine cell, but is due to an additional component found on the human cell. 
Work several years ago has shown that CD8 lymphocytes suppress viral replication 
in PBMC 's 142 . It was later shown that the CD8 were actually secreting one or more 
soluble HIV suppresser factors ' 43 . These suppression factors were finally shown to be 
the chemokines RANTES (regulated-upon-activation, normal T expressed and 
secreted), MIP-la (macrophage inflammatory protein-la), and MTP-113''. Both 
MTP- Ia and MIEP- 10 have been shown to be released in early infection to allow the 
creation of an inflammation centre 145 . It is unfortunate that this leads to the presence 
of T cells giving a fertile environment for the spread of WV. Further proof came from 
the work of Broder et al 146  who showed that viral tropism restrictions occur at the 
membrane fusion level after the binding of gp 120 to CD4, again pointing to a cellular 
component acting as a co-receptor. All the above evidence was pointing to the 
presence of a secondary (co-)receptor on the surface of the cell. 
Epidemiological studies have shown that certain individuals do not become infected 
with HIV, even after multiple exposure from HIV infected partners ' 47 . Further studies 
have shown that this relative resistance to FIIV infection was only to macrophage 
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tropic viruses, and it was not due to an intrinsic resistance of cells from the exposed 
individual to }{IV infection which were easily infected with T-cell tropic viruses 148 . 
The breakthrough came with the findings of Feng et al 149,  who showed that T-cell 
tropic HIV was using a secondary receptor, variably named fusin, LESTR (leukocyte 
derived seven transmembrane domain receptor) or CXCR-4. The presence of fusin 
together with human CD4 on the surface of the cell, allowed non-humah cells to 
support fusion and infection with T-cell tropic isolates. indeed, the presence of 
antibodies to fusin lead to the blocking of cell fusion, but not binding of the gp 120 to 
CD4 in those same cells. Continuing research showed that murine, feline, simian and 
quail cell lines could all support fusion and infection in the presence of both flisin and 
human CD4 150. The receptor has been known for several years 15 ', but the ligand was 
unknown. After the HIV findings, the ligand was identified as stromal cell-derived 
factor-i (SDF- l)152153.  The presence of this ligand has been shown to block T-cell 
tropic fusion with human PBMC's. The sequence of SDF- 1 was also well known 154 
and was found to be a chemokine expressed in a broad range of tissues 155 . 
This work showed that T-cell tropic viruses used fhsin as a co-receptor, thus it 
seemed logical that M-tropic HIV was highly likely to do the same by using a different 
receptor. Since M-tropic viruses could be blocked by the presence of the chemokines 
RANTES, MIIP-ia or MIP-13, a receptor to these three chemokines was the obvious 
candidate. A newly discovered receptor was known to bind these three chemokines 
exclusively, namely CC-CKR5 (for CC chemokine, chemokine receptor 5)156  This 
receptor was then co-transfected and expressed with human CD4 on the surface of 
CC-CKR5 -ye cells. The presence of this receptor led to M-tropic viruses 
productively infecting non-macrophage and even non-human cells ' 57"58"59"60"61 . It 
should be noted that this infection was almost totally retarded in the presence of the 
three chemokines named above. Work also showed that the patients who were far less 
susceptible to M-tropic IIIV infection either had an overproduction of the chemokines 
secreted from CD8 cells 162,  or actually had a defective CC-CKR5 allele containing a 
deletion 163 . Presumably this deletion leads to the inability of the virus to use the co- 
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receptor and hence disruption to fusion and replication. It should be noted that, 
although CC-CKR5 seems to be the major co-receptor to M-tropic HIV, there are 
indications that other chemokine receptors may be used although much less 
effectively. 
Interestingly, the work by Doranz et al 143  showed that CC-CKR5 was the co-receptor 
for M-tropic HIV, and that a dual tropic HTV isolate could use both fusiii and CC-
CKR5 as entry cofactors. As the interaction of gp 120 with the different cofactors 
changes the tropism of the virus, and the tropism is so markedly affected by the 
sequence of the V3 loop (see earlier), it is highly likely that the V3 loop is interacting 






	 Cellular cytoplasm 
Figure 1.13 
Interaction of Fusin with gp 120 in T-cell tropic fusion 
(Adapted from ref 164). 
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1.3 Peptide synthesis 
Peptides and proteins are an all pervasive class of organic molecules found in many 
areas of life. They are natural polymers, coded for by nuclear DNA. They are used by 
the body in widely differing ways, controlling neurological, immune, endocrine and 
synthesis processes. Biological catalysis is carried out by a specific set of proteins, 
known as enzymes. The study of the folding and interaction of these protein -S can give 
an insight into many biological areas. For instance, there is a real opportunity to affect 
a disease state with the use of synthetic proteins, either as agomsts or antagonists. 
Peptides can be designed such that the structure mimics the active site of a protein, 
allowing the introduction of such a site without the excess scaffolding usually 
accompanying it. This can then be used to raise antibodies which cross react with the 
native protein. 
In nature, the protein is synthesised inside the cell using specific areas of DNA, the 
DNA having been previously transcribed to RNA for use as a template. It is formed 
by attachment of one amino acid to the next in the chain, the sequence running from 
the N terminus to the C terminus. The biological expression of proteins is an excellent 
way of obtaining proteins in relatively large amounts, especially with the use of 
overexpression technology. The great advantage of chemical synthesis of proteins 
over their expression is the ability in chemical synthesis to incorporate unnatural 
amino acids, i.e. ones not coded for by any DNA, and as such is an extremely flexible 
way into the enormous field of protein technology. 
Peptide synthesis began using the techniques of the solution phase many years ago. It 
comes as a surprise to learn the first reported peptide synthesis was performed in 
1901 with the formation of glycylglycine' 65. The synthesis of peptides using the 
solution phase was extremely complex and fraught with problems, each of the 
intermediate compounds having to be isolated and purified. By the 1950's, peptides 
were readily being synthesised 166,167,168 , but it was obvious to those involved that 
solution phase would be impossible to use for large proteins and synthesis of the 
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proteins utilising solid phase was likely to be the way forward 169. It was for this 
reason that Merrifleld's work 170  made such a huge impact. His simple and extremely 
elegant idea was to anchor the growing chain covalently to a solid resin particle, 
thereby allowing the removal of by-products and leading to the crystallisation of 
intermediates becoming increasingly unnecessary. 
Peptides are biological polymers and can be thought of as a string of amino acids 
linked together using the amide bond (see Figure 1.14). 
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Figure 1.14 
The amide bond 
Thus the synthesis of proteins and peptides can be thought of as the synthesis of 
amide bonds. Of course it is more complicated than that, with the bonding needing to 
be specifically between one amine and another carboxylic acid. The amino acids must 
be activated in order for them to form an amide bond. Protecting group strategies 
must be employed to ensure the correct bond is being formed, as in the following 
example. 
Suppose two amino acids are used to form an amide bond. Both have amino and 
carboxylic acid groups. This leads to there being four ways for the amide bond to 
form, as shown in figure 1.15. 
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RI 	R2 
R1R1 and R1R2 and R2R1 and R2R2 
Figure 1.15 
Amide bond formation between two amino acids R 1 and R2 
It should be noted that even this is a simplified version of the reactions occurring. 
Further reaction of the products above could lead to trimers, tetramers, etc. If the 
required product was R,R2, then the amino group of R, must be blocked, and specific 
activation of the carboxylic acid group of K 1 must be achieved, with the carboxylic 
acid group of K2 being blocked. Not only that, many of the side chains of ammo acids 
are also reactive in the conditions used for amide bond synthesis. This leads to the 
necessity for protection of these side chains as well. 
In the initial paper by Merrifield, the solid phase synthesis of a tetrapeptide was 
reported. The synthesis used the Z group 171  for Na protection, the group being 
removed with 30% HBr in acetic acid 172. It was found that the group was not fully 
removed and in later work 173  Merrifield used Boc 174 protection which cleaved easily, 
in TFA, due to the formation of the stable t-butyl carbocation (see Figure 1.16). 
Q OCO2H 	 OCO2H 
OR 	 OR 
Benzyloxycarbonyl 	 tButyloxycarbonyl 
protection (Z) 	 protection (Boc) 
Figure 1.16 
Acid cleavable Na protection 
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The overall synthetic pathway that Merrifield adopted is shown in Figure 1.17. Note 
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Figure 1.17 
Merrifield initial approach to a dipeptide 
The major advantages of solid phase synthesis can be seen from the above diagram. 
Between each cycle, the solid resin allows several washing steps to remove by-
products and unreacted activated amino acid. Unfavoured coupling reactions can be 
forced by the use of large excesses of starting material. Also, the fact that the peptide 
is suspended on a resin means, due to the mutual solvating effect of the peptide chain 
and the polymer chain, the peptide is thermodynamically less likely to self 
aggregate 175 . 
Activation of the acid to allow coupling was carried out in the above example using 
the acid anhydride. This in turn is formed using N,N' dicyclohexylcarbodiiniide' 76 (see 






1.3.1 The Boc strategy 
This remains relatively unchanged from the initial work carried out by Merrifield. The 
support used is still styrene copolymerised with 2% divinylbetizene as a cross linking 
agent. This was chosen as it contains all the characteristics required in solid phase 
synthesis. These are outlined below. 
The resin swells in organic solvents to up to five or six times its original 
volume, allowing free accessibility of the growing peptide chain to diffusing 
reagents, leading to fast reaction times. 
The resin is stable to all conditions used in the synthesis 
The resin is able to be fimctionalised, to allow attachment of the peptide. 
As the peptide chain grows, the dry volume of the resin increases to 
accommodate the added mass. 
The initial amino acid is coupled to the resin via its caesium salt by nucleophilic 
displacement of chlorine. Na  protection is afforded using the Boc group already 
mentioned. Removal of the Boc group prior to coupling is achieved using the 
relatively mild acid, TFA. The linker and side chain protecting groups are also acid 
cleavable, but are much less susceptible to cleavage. Thus, the TFA removal of Boc 
leaves the linker mainly unaffected. Neutralisation then leaves a free amino from 
which the further assembly can grow. The coupling of the subsequent Boc protected 
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amino acid is carried out using the carbodiinide grouping discussed above. The 
synthesis is cycled, with the peptide growing from the C to the N terminus, until the 
required peptide is present. BF is then used to cleave the peptide from the resin and 
deprotect the side chains. 
Boc chemistry is an extremely powerful way to synthesise proteins and peptides, but it 
is not perfect. Improvements could come from the use of less drastic reagents, HF 
requires special glassware and very careful handling, and the side chain protection and 
the linker are not orthogonal to the N protection. As they are all affected by acid, the 
constant cleaving of Boc with TFA, however relatively mild, will lead to loss of 
peptide from the resin. There have been attempts to synthesise more acid labile N 
protecting groups to minimise this problem, an example being the Bpoc group 117 
shown in Figure 1.19. The Bpoc group was used for demanding syntheses, however 
the problems still arose from non orthogonality. This led to the attempt to find a base 
labile protecting group for solid phase synthesis and from there to the discovery and 
the use of Fmoc in solid phase peptide synthesis. 
C{HO A N' R 
Figure 1.19 
The Bpoc group 
1.3.2 The Fmoc strategy 
9- Fluorenylmethoxycarbonyl (Fmoc) group is a base labile protecting group used in 
solid phase peptide synthesis. Initial work by Bergmann and Zervas' 71, and later by 
McKay and Albertson 174  showed the use of urethanes as protecting groups for amines 
in peptide synthesis. However, the groups that came from this work, including Boc, 
were cleaved under acid conditions to the carbamate, which then spontaneously 
decarboxylates to the free amine. Carpino and Han ' 78, however, used the urethane 
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work and the process of 13 elimination to give a protecting group cleavable under 




An Fmoc protected amino acid 
It was rapidly shown that the group was stable to acids and hydrogenation, and was 
easy to introduce using the chloroformate' 79, although the N-hydroxysuccinimide 
ester is now more usually used giving a cleaner reaction. The group gave total 
orthogonality between the linker and the amine protection. 
This orthogonality allowed the introduction of acid labile protecting groups and 
linkers. t-Butyl ester and Boc groups could now be used as protection, together with 
the p-benzyloxybenzy alcohol linker 180. This is an extremely acid labile linker shown 
below (see Figure 1.21). 
HO JQn 1 
Figure 1.21 
p-Benzyloxybenzyl alcohol (Wang) resin 
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The rapid cleavage of this linker by mild acid (e.g. TFA) can be explained by the 












Acid cleavage of the Wang resin 
The relatively mild cleavage and deprotection conditions led to the synthesis of 
peptides whose purity and yield was much improved 181 
Cleavage of the Fmoc group occurred by 13-elimination using an E1cB 
mechathsm 1 " 83" 84 , via the stabilised dibenzocyclopentadienide anion. The anion then 
breaks down to the dibenzofulvene and the carbamate of the peptide. The carbamate 
formed then readily decarboxylates to give the free amine. The dibenzofhlvene reacts 
with piperidine to give the piperidide adduct. This adduct absorbs strongly in the UV, 
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Pip eridide adduct 
with the isosbestic point at 302 nm 185  This can be used to follow the amount of amino 
acid coupled at each step and hence give a real time assessment of the progress of the 
synthesis 186187. All syntheses discussed in this work have used this method for 
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Figure 1.23 
3 elimination of Fmoc by piperidine 
The use of this base labile protecting group was soon found to give comparable 
incorporation of the amino acids  188  and indeed to be complementary to Boc chemistry. 
Thus this method was widely adopted and improved 189 . 
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1.3.3 Activation of ammo acids 
In most cases in peptide synthesis, the formation of the amide bond is effected using a 
nucleophilic displacement reaction. This approach requires a more effective leaving 
group than the hydroxyl present on the carboxylic acid. The usual way to obtain this 
effective leaving group is to substitute the hydroxyl for a more electronegative 
substituent, E 190,191 . This gives a reaction as in figure 1.24. 








Activation and coupling of an amino acid. 
(P = protecting group, E = electronegative substituent) 
There are many ways to activate the amino acid. Comprehensive reviews on the 
subject have been written' 92"93"94, and a fill discussion is beyond the scope of this 
introduction. A few of the methods will be discussed below. 
1.3.3.1 Acyl chloride 
Early on in the synthesis of peptides, acyl chlorides were used extensively 195  however, 
formation of an acyl chloride is difficult in the presence of sensitive substrates and the 
Z amino acid chlorides are unstable. Fmoc amino acid chlorides, however, have been 
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N,O 	- 	 Racemisation 
Oxazolone 
Figure 1.25 
Racemisation of acyl chlorides 
This is a general rearrangement for all N  urethane protected, activated amino acids. 
The rearrangement can be reduced using less reactive leaving groups. It becomes a 
major problem with the acyl chlorides due to the extremely electronegative chloride 
ion. This leads to the formation of the oxazolone being more facile than reaction with 
the amine group. 
1.3.3.2 Acyl andes 
The use of acyl andes were also introduced at the turn of the century '96. The azide is 
less reactive than the acyl chloride and hence the formation of the oxazolone is 
disfavoured relative to amide formation. The major drawback of azide use is the 
rearrangement of the azide to form the isocyanate. Further reaction of the isocyanate 
is then possible as shown in Figure 1.26. This led to the azide method going out of 
favour when cleaner methods of synthesis became available. The azide method has 
recently enjoyed a resurgence due to its use in chemical ligation to form large 
proteins 197 
38 







Curtius rearrangement of acyl andes 
1.3.3.3 Carbodiimides 
Ever since the initial report of the use of dicyclohexylcarbodiiniide (DCC) in the 
synthesis of peptides 176, the use of carbodiimides in peptide synthesis has become 
widespread. Solid phase synthesis has tended to favour diisopropylcarbodiiniide 
(DIC) 198 purely because the urea formed after reaction is more soluble in the DMF 
than the N,N' -dicyclohexylurea formed by DCC, allowing easy removal. Their use can 













= -OC(0)- , product = anhydride 
X = -NH- 	, product = peptide 
X = -0- , product = active este 
Figure 1.27 
Use of DIC to form anhydrides, peptides 
and activated esters 
Addition of the amino acid to the DIC leads to the formation of an 0-acylurea, giving 
an extremely potent acylating group. Direct coupling of a free amino group from 
another amino acid is possible to give the desired amide bond. More usually, the 
reactive 0-acylurea is further reacted with either another carboxy group to give the 
symmetrical anhydride (R1R2), or alternatively with a phenol to form an activated 
ester. Problems stem from the high reactivity of the 0-acylurea since intramolecular 
acyl transfer can compete with the desired attack by external nucleophiles. This leads 
to the formation of the N-acylurea, coupling of which will lead to problems with 






N-acylurea formation from 0-acylurea 
Specific rearrangements occur to certain amino acids, such as dehydration of 
asparagine/glutamine, to give the nitrile, by the mechanism shown in Figure 1.29. This 
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Figure 1.29 
Asp aragine dehydration upon 0-acylurea formation 
To stop these rearrangement problems, and the extensive racemisation which can 
occur with susceptible carboxy components, the 0-acylurea is reacted quickly with 
another equivalent of the amino acid to form the symmetrical anhydride, as described 
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below. Alternatively, the 0-acylurea can be reacted with a phenol to give a less 
reactive species, but still reactive enough to undergo aminolysis. The hydroxy 
compound must readily react with the 0-acylurea, but also must be a good leaving 
group in its own right. These activated esters will be discussed later. 
1.3.3.4 Symmetrical anhydrides 
Symmetrical anhydrides are used fairly extensively in solid phase peptide synthesis in 
this laboratory. They are easily formed from two equivalents of the required amino 
acid, together with DIC, as described above. They lead to unambiguous aminolysis of 
the required amino group due to their reactivity. The major drawback in their use is 
the discarding of one equivalent of expensive amino acid per coupling cycle. Serious 
side reactions can occur with certain amino acids, the problems occurring with Asn 
and Gin have already been discussed. 
1.3.3.5 Active esters 
Active esters were initially synthesised to curtail the waste of reactants inherent in the 
use of symmetrical anhydrides. There are several different types of active esters, 
reviewed in reference 192. The most important consideration in the use of active esters 
is the leaving ability of the ester group, as discussed earlier. Hence, some of the first 
compounds used were o- and p- nitrophenyl esters 200. This has led to several esters 






Nitrophenol 	 Trichiorophenol 	Pentafluorophenol 
alcohol (Np) alcohol (Tcp) alcohol (Pfj) 
Figure 1.30 
Derivatives of phenol used in active ester formation 
Other esters have been introduced not linked to the nitrophenol ester, but they all 
have characteristics of being electron withdrawing. The ones most used are HOSu 202 
and HOBt203, shown below (Figure 1.31). 








HOBt reacts quickly with the 0-acylurea as shown in Figure 1.33. This leads to the 
formation of the HOBt ester which is much less reactive than the symmetrical 
anhydride. This reduces the side reactions inherent in the use of carbodiimide already 
discussed. HOBt ester formation also inhibits the rearrangement to the nitrile seen 
with Asa and GIn amino acids204 '205 . More recently, there has been work on new 
activated esters using HOBt as a template. In particular, the work on HOCt 206'207 has 
given rise to activated esters more reactive than their HOBt counterparts. Also, the 
smaller size of the HOCt alcohol (see Figure 1.32) allows quicker reaction with the 0-









Active esters are mainly formed via DIC mediated coupling, reacting with the 0-
acylurea intermediate. 
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activated ester 	 urea 
Figure 1.33 
Formation of HOBt activated ester using DIC 
1.3.4 Side chain protection 
As stated earlier, the mild acid cleavage required for the Wang resin allows the use of 
more acid labile side chain protection. This protection is mostly via t-butyl esters or 
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ethers. Certain amino acids, such as cysteine, need to be orthogonally protected to 
allow for further reaction after cleavage. The most used protecting groups in Fmoc 
synthesis are shown in Figure 1.34. 
Amino acid Side chain protection 






His 7c-Bum209 , t-Trt210 
Cys Trt211 , Acm212, SBut 2 l3 
Asn and Gin Mbh214 , Trt' 99 
Figure 1.34 
The usual Fmoc side chain protecting groups 
All other amino acids have no need for side chain protection, as they are unaffected by 
the conditions used for Fmoc coupling. 
1.3.5 Acid Cleavage 
Once chain assembly is completed, the peptide is cleaved from the resin at the same 
time as the side chains are deprotected. Usually TFA is used to affect this cleavage, 
although stronger acids such as TFMSA215 have also been used. Deprotection of these 
side chains leads to the release of reactive carbocation intermediates. These can easily 
react with the peptide in an irreversible manner to form adducts which are difficult, if 
not impossible to break down. To counteract this effect, carbocation scavengers are 
added to the cleavage mix. These are small nucleophilic molecules, able to react with 
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the carbocations before they react with the peptide. The identity and mix of 
scavengers used depends upon the amino acids and hence the carbocations present. 
Scavengers used regularly include water, 1,2-ethanedithiol (EDT), thioanisole and m-
cresoL 
1.3.6 Rearrangements 
Rearrangements specific to the formation of an activated amino acid have already 
been covered. Specific rearrangements due to the length of the peptide chain or the 
presence of specific amino acids or sequence of amino acids include the following. 
1.3.6.1 Histidine racemisation 
The basic ring of the side chain in histidine leads to the possibility of proton 
abstraction intramolecularly from the backbone, as shown in Figure 1.35. This leads 
to reprotonation from the top or bottom face and hence loss of chiral integrity. 








Protection of the side chain is used to either reduce the basicity of the ring, as in t-
Trt, or sterically blocking the it nitrogen, as in it-Bum 209 
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1.3.6.2 Diketopiperazine formation 
Upon formation of a dip eptide and removal of the Fmoc protection in the usual way, 
the presence of certain amino acids in the dipeptide, mainly glycine, leads to attack of 
the peptide resin ester linkage by the free amine., as in Figure 1.36 below. 
Pro 
R/ j O *\%{j sin 
HN- 
RI 	0 




1.3.6.3 Aspartimide formation 
This is a rearrangement which has caused major problems in the following work. It is 
discussed in detail later. 
1.3.7 Overall Fmoc synthesis 
The synthesis of peptides using the Fmoc strategy can thus be summarised as in 
Figure 1.37 below. 
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H2N) -  --------- NNOH 
Figure 1.37 
Fmoc synthesis 
(a) attachment of first activated amino acid, (b) Na deprotection, (c) coupling of next 
activated amino acid in the chain, (d) repeat until the required sequence is present, (e) 
removal of final Na protection, (f) cleavage and deprotection of side chains 
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Chapter 2 : Results and Discussion 
2.1 Project overview 
The impetus for this work comes from the desire to obtain information which may 
lead to the formation of a vaccine against AIDS, a disease fast becoming one of the 
most urgent medical emergencies to affect the human population. It took eight years 
for the first 100 000 cases of AIDS to develop in the US, the second 100 000 took 
just two years. H1V has now become the second biggest killer of twenty to thirty year 
olds in America (See Figure 2.1). Thankfiully, after many years of little success, there 
have been great advances in the treatment of FIIV infected individuals in the last six 
months. In particular, combination therapies using reverse transcriptase inhibitors and, 
more recently, the use of protease inhibitors have led to a relative lengthening of life 
expectancy in the developed world. Unfortunately, not only do these therapies lead to 
a relatively small increase in lifespan, they are also prohibitively expensive for use in 
countries where HIV has had the most devastating effect, namely Africa. The high 
mortality rate among young working adults there has caused an economic downturn 
and left more than a million children orphaned. It is therefore essential, especially in 
the African case, to find a preventative procedure rather than attempt to treat the 
subsequent illness. 
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Figure 2.1 
Mortality rates per 100,000 people 
for 20-30 year old males in the USA 
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Vaccine technology has advanced greatly since its discovery by Jenner over two 
hundred years ago. This has led to the irradication of diseases which were the scourge 
of humanity for many centuries. However, the use of the usual vaccine treatments 
such as attenuated or whole killed viruses is out of the question with such a highly 
pathogenic virus as HIV. Not only that, along with areas of gp 120 that are relatively 
conserved between different isolates 86, the virus contains areas which are highly 
variable. Antibodies to these areas are necessarily type specific and therefcfre useless 
for the broad neutralisation needed to eliminate the virus. The virus is in effect using 
its high replication rate and high variability to 'hide' from the immune system. 
As stated earlier, the initial interaction of HIV with the target cell involves high 
affinity binding of the coat protein gp 120 to the cell surfce receptor CD4 49 ' 50' 51 ' 52 . 
This interaction is obviously crucial for the overall infection pathway of the virus and 
is thus an attractive target for intervention 133 . Interference with binding will halt the 
whole process of infection in effect before it is even begun. Synthetic peptides are 
known to be capable of eliciting a specific immune response which will cross react 
with the intact native protein'. Thus a peptide mimicking the 3D structure of the CD4 
binding site on gp 120 could initiate a humoral immune response leading to antibodies 
capable of cross reacting with the native virus. This would overcome many of the 
problems of a vaccine approach to HIV. In particular the CD4 binding site has been 
shown to be constant, leading to a vaccine effective across all viral isolates. 
There have been a great number of gp 120 peptides already synthesised and although 
many were able to raise antibodies which neutralised the virus in vitro, they were 
unable to neutralise in vivo. This is probably due to the antibodies being raised to 
peptides equating to linear epitopes. It has already been shown that all epitopes on 
proteins are discontinuous to a certain extent 18. Indeed the only characterised broadly 
neutralising antibodies raised in the course of HIV infection are raised to 
discontinuous epitopes92 ' 216 ' 217 , and the CD4 binding site itself is discontinuous 89 . 
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This research described herein is a continuation from that of Dr G. J. Cotton218 , 
consisting of the synthesis of a peptide designed to mimic this discontinuous region of 
gp 120. Olshevski et al have shown by point mutation studies that the CD4 binding 
site on gp 120 has five amino acids essential for efficient interaction. Further 
confirmed that these five amino acids were indeed close in space in the folded protein. 
The peptide synthesised, named (IC 1, contains three of the five amino acids and a turn 
designed to present discontinuous along with linear epitopes. The Cys(378)-Val-
Cys(445) turn was chosen as this had been shown to oxidise readily 219 ' 220. GC1 is 
shown in Figure 2.2 below. The synthesis of (IC! will be improved and variants 
synthesised to study the affinity of binding both with soluble C134, cells expressing 
CD4 on their surface and also to study the bodies immune response to the 
aforementioned peptides. The peptides are designed to mimic the discontinuous 
binding site of C134 on gp 120 to a greater or lesser degree. 
(a) 
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Figure 2.2 
(a) C3 and C4 regions of gp 120 showing the closeness in space of the aforementioned 
amino acids. (b) (1(21 showing how the peptide mimics the overall gpl2O structure 
(Adapted from Ref. 218) 
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2.2 GC1 synthesis : The problems 
The coupling of each amino acid in the stepwise synthesis of (IC 1 is afforded in high 












The coupling profile for a normal 
synthesis ofGCl 
Although the coupling is maximised, the synthesis of (IC 1 is not as straightforward as 
would be expected for a peptide of its size. The initial work in this project 
investigated maximising the yield, which was affected by two major factors. Firstly, 
the purification requires three separations by preparative HPLC. At each there is loss 
of around 50% of the peptide. The cumulative effect is a large loss of material and 
thus, the reduction in the number of purification steps is a priority. The major problem 
in the synthesis is the loss of material via a side reaction initiated by the base 
deprotection of the a-nitrogen, namely the Asp-Gly rearrangement. 
2.2.1 The Asp-Gly rearrangement 
The rearrangement of peptides containing the Asp-X motif where X is a small amino 
acid, in the presence of acid or base has been known for many years 221 '222'223 . It is 
Oi l 
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observed in both Fmoc and Boc chemistry and is a problem not completely solved. 
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The aspartimide rearrangement in base 
The presence of base leads to an increased nucleophilicity of the backbone nitrogen, 
allowing cydisation onto the carbonyl of the asp artic acid side chain. This attack and 
expulsion of the protecting t-butyl ester leads to the formation of the aspartimide. 
This can be ring opened by nucleophilic attack. Water present in the cleavage and 
deprotection procedures can open the aspartiniide to form either the cx or the - 
peptide. Similarly, the piperidide base can ring open. However, due to stenc 
considerations, the -piperidide predominates. 
Thus the presence of the Asp-Gly motif leads to rearrangement during the Na-Fmoc 
base deprotection, before the coupling cycle. Cotton 218  showed that changing the base 
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used for the deprotection, or the deprotection times did not alleviate the problem 
sufficiently. 
The Asp-Gly motif in GC 1 has led to enormous problems over the years due to the 
above rearrangement. After cleavage and deprotection of the peptide from the resin, 
three main products are discernible, instead of the one major product usually seen in a 
linear peptide of this length. The desired product, GC1 (Cys-Acm), was asmall part 
of the overall crude yield (see Figure 2.5). 
Figure 2.5 
IIPLC trace showing the products obtained 
due to the rearrangement of GC 1 
There have been several attempts at producing novel protecting groups which would 
negate this effect. The rearrangement is so facile when X is a small amino acid due to 
the ease in which the deprotonated backbone nitrogen can reach the protected side 
chain. The main attempts at reducing this rearrangement involve either increasing the 
steric interaction between the backbone nitrogen and the side chain, or removing the 
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Increasing the steric bulk of the side chain protecting group has been attempted 224 . 
More recently, coupling of the troublesome glycine to the large 2-chiorotrityl resin 225 
has led to the same effect (see Figure 2.6(a)). This procedure necessitates the C-
terminus of the synthesised peptide to be the glycine of the Asp-Gly motif; coupling 
the amino acids beyond to the C terminus in a later step. The use of amide bond 
protection using the 2-hydroxy-4-methoxybenzyl (Hmb) group 226'227 has also been 
used to give a high degree of suppression of the rearrangement (see Figure 2.6(b)). 
Unfortunately, Hmb protected glycine is still very expensive and therefore unsuitable 
for regular use. 
(a) The use of 2-chiorotrityl resin 
	
(b) The use of Hmb 
backbone amide protection 
Figure 2.6 
Asp artimide rearrangement reduction 
Martinez and Bodansky 222 mentioned an efficient suppression of aspartimide 
formation in Boc chemistry. They added an equimolar amount of tertiary amine to the 
TFA used to remove the Na-Boc protection. It was presumed the base was acting by 
buffering the acid. Doling et a1228 used this information in Fmoc chemistry. They 
found that the addition of 0. 1M of either 2,4-dinitrophenol or HOBt to the Fmoc 
deprotection solution gave efficient suppression of the aspartimide formation, 
presumably by buffering the deprotection solution. This technique was found to be an 
efficient way of suppressing asp artiniide formation to workable levels in GC 1 and 
related peptides. 
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The synthesis of GC 1 was repeated using 0. 1M HOBt in the solution of 20% 
piperidine in DMF. The synthesis was monitored at 302nm in the usual way and was 
observed to give good coupling at each amino acid cycle (see Figure 2.7). Real time 
assessment of coupling efficiency was affected due to the UV activity of the HOBt 
molecule at A=302nnt However, as the concentration of HOBt is constant throughout 
the three deprotections in each cycle, its activity could be removed to give an 
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Figure 2.7 
Coupling profile of GC 1 synthesised in the presence of 
0. 1M HOBt in the Na deprotection solution 
The synthesis was completed and the peptide was cleaved from the resin in the usual 
way. This led to a crude peptide mix giving an HPLC trace as shown in Figure 2.8, 
indicating the rearrangement problem had been reduced to manageable levels. 
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Figure 2.8 
HPLC trace of crude (IC 1 synthesised 
in the presence of 0. 1M HOBt 
A reduction in the number of preparative HPLC steps required was attempted. The 
initial work involved the use of different cysteine protection and the use of a novel Nu 
protecting group, Thflnoc, which has properties which facilitates purification. 
2.2.2 Cysteine protection : The use of the cysteine-phenylacetamidomethyl 
(Phacm) group 
Cysteine protection orthogonal to the usual acid deprotection was utilised throughout 
this project. It had been found earlier that there was a tendency for intermolecular 
oxidation during cleavage if the acid cleavable trityl group was used 2 ' 224 . Also, the 
use of Thfmoc in the presence of free cysteines causes considerable problems 229 . 
Cysteine protection utilised included Acm 212 and variants of the phenacetyl group 
previously used in cysteine side chain protection 229, lysine side chain 
protection ' 97" °'' and the aminoprotection of purine nucleosides 2 . Use of this 
protecting group would allow enzyme removal to be examined. The removal of Acm 
is usually achieved with silver triflate233, mercury acetate or thallium 







Penicillin G 6-aminopenicillanic acid 
salt of the peptide, the peptide itself being released by treatment with dithiothreitoL 
This reaction necessitates a fhrther HPLC step to remove DTT salts and still 
protected peptide. 
Penicillin acylase catalyses the hydrolysis of penicillin G into 6-aminopenicillanic acid 
and phenylacetic acid 234  (see Figure 2.9). 
Figure 2.9 
The hydrolysis of penicillin G 
The enzyme is highly specific at the aromatic carbonyl side of the amide bond, yet 
highly tolerant of substrates variation at the amine side of the amide bond 23 ', allowing 
the use of a phenacetyl derivative on the side chain of lysine. This reaction was also 
seen to work with the sulfur of cysteine 229 , giving the protecting group shown in 
Figure 2.10. This enzyme can be attached to a solid support to allow for easy removal 
from the reaction mix without affecting substrate specificity 235 ' 236'237 , perhaps allowing 
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Figure 2.10 
The use of phenacetyl-like protection 
on cysteine 
Thus the Phacm group was used as the cysteine orthogonal protection in the synthesis 
of GC 1 to evaluate its use and enzyme removal. 
The synthesis of (ICI using Phacm protected cysteine was carried out in the usual 
way, with 0. 1M HOBt present in the solution of 20% piperidine in DIVIF to reduce the 
aspartinñde rearrangement to a minimum. The synthesis proceeded well to conclusion, 
with the coupling profile showing few problems (see Figure 2.11). Upon cleavage and 
deprotection, the protected peptide (IC 1 (Cys-Phacm) was relatively easily isolated 












Coupling profile of (3€! (Cys-Phacm) 
Upon isolation of the cysteine-protected peptide, the removal of the Phacm protection 
was attempted with immobilised penicillin acylase. The peptide was suspended in 
buffer at pH 8 and incubated at 37°C for 24 hr with the resin-bound enzyme, the 
optimum conditions for its use. HPLC was used to monitor the reaction. 
Unfortunately, the Phacm protection was unaffected by these conditions, leaving the 
peptide in much the same state. Due to this peptide's ability to undergo aspartimide 
rearrangement, the reaction could not be continued for any extended length of time at 
the optimum pH. It seems likely that the presence of two Phacm groups close 
together were blocking insertion of either of the groups into the stencally demanding 
active site of the enzyme. l'his has been shown to be a long cleft found at the centre 
of the kidney-shaped molecule 23". Thus, the Phacm protected cysteine could not be 
used in conjunction with enzyme deprotection in this case. 
Removal of the Phacm protecting group using the usual deprotection protocols was 
attempted. Mercuric acetate 21 ' and silver triflate 233 were both used in an attempt to 
obtain the reduced, deprotected form of GC 1. Mercuric acetate deprotection 
produced a peptide with mass as in Figure 2.12. The Phacm groups had been removed 
from the peptide, but upon DTT treatment to liberate the peptide from its mercuric 
salt, and gel column treatment, only a small amount of free peptide was recovered, the 





Mass spectrum from mercury deprotection ofGCl Cys-Phacm 
Silver triflate deprotection was attempted using the usual protocol, as described in the 
experimental section. Complete removal of the Phacm group was not achieved using 
this technique and analytical HPLC showed a collection of peaks (see Figure 2.13). 
Figure 2.13 
HPLC trace of silver triflate deprotection ofGCl (Cys-Phacm) 
2.2.3 Na-Thfmoc protection in purification of G4C1 and its analogues 
One of the main problems with any synthetic peptide synthesis is the separation of the 
final product from the truncated peptides present. Thfinoc methodology was 
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introduced to utilise the fact the desired product should be the only peptide with an N 
terminus not acylated. Thfmoc was synthesised first by Ramage and Raphy 239 and 
improved upon by Brown et a1240. It has been shown that this group could be used for 
the purification of oligonucleotides 24 ' and peptides ' 87 . The use of the Thfmoc group 
was attempted in the synthesis of GC 1. 
The Thfmoc group has the structure as shown in Figure 2.14. The large aromatic 
nature of the group leads to a high affinity for porous graphitised carbon (PGC) 242 , 
and an increase in retention time on HPLC when attached to proteins. Fmoc is 
removed from the completed peptide whilst still on the resin using a solution of 20% 
piperidine in DMF containing 0. 1M HOBt. The chloroformate of the Thf group is 
sonicated with the resin in dioxane in the presence of equimolar amounts of DIEA. 
The resin is washed and the fluorescence of the group at 364nm is used to determine 
the percentage loading of the Thfmoc moiety. Once satisfactory loading has been 
achieved, approximately 100%, the peptide is cleaved from the resin and deprotected. 
Scavengers are removed using gel chromatography, and the peptide loaded • onto 
PGC. The peptide containing the Thflnoc group is adsorbed onto POC, and the 
truncated peptides removed by copious washing. The desired product is then released 
from the resin using a basic solution of guanidine hydrochloride. Upon removal of the 
salt, again using gel chromatography, the desired product can be recovered by 
lyophilisation. 
Figure 2.14 
Thfmoc in peptide purification 
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Thfmoc loading to (liC 1 was never satisfactory, something which is presumably down 
to folding on the resin after removal of the Fmoc group. This led to only partial 
tagging of the desired product, and increased difficulty in purification and, after 
several attempts to improve the coupling of the TV chioroformate to the resin, this 
method was abandoned. 
2.3 Optimised GC1 synthesis 
The work carried out on cysteine protection and Thfiioc assisted purification were 
not incorporated in the enhanced synthesis of GC1. The suppression of the 
aspartimide rearrangement, together with the silver triflate removal of Acm in the 
presence of scavengers, the isolation of the Acm protected peptide becoming 
unnecessary, has led to the synthesis of large amounts of the difficult peptide, GC 1. 
Synthesis of (3C1-Acm was carried out on a 0.5mmol scale using DIC to form the 
tnazole activated ester. Histidine was coupled as the HOBt activated ester thus 
reducing racemisation. All amino acids were double coupled. Removal of the Acm 
group using silver triflate233 led to isolation of (IC1.reduced, i.e. peptide prior to 
cystine bond formation (see Figure 2.15). 
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Removal of Acm with silver triflate in TFA 
Oxidation and formation of cystine was carried out using 2.5% DMSO in TFA as in 
the protocol of Tam et a1243 (see Figure 2.16). 
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Cysteine oxidation using DMSO 
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Oxidation led to the formation of GC 1, which was isolated using preparative HPLC. 
gave an analytical HPLC trace, mass spec, Eliman's assay and amino acid analysis 
identical to that synthesised by Cotton 218  (see Figure 2.17 and 2.18). 
Amino Acid Expected Found Amino Acid Expected Found 
Asx 4.00 4.18 Val 2.00 1.79 
Thr 3.00 3.18 Ile 2.00 1.66 
Ser 5.00 4.67 Leu 3.00 3.29 
Gix 1.00 0.98 Phe 1.00 0.98 
Pro 1.00 0.92 His 1.00 1.11 
Gly 5.00 5.22 Lys 1.00 1.38 
Cys 2.00 0.67* Arg 1.00 1.12 
Asx = Asp and Asn, GIx = Glu and Gin. *Cyeine  result is uncorrected. 
Figure 2.17 










Data obtained on GC 1 
M. 
2.4 Synthesis of GC1 analogues 
As explained earlier, point mutation studies by Olshevsky et at led to the realisation 
that there are five amino acids crucial for high affinity binding of gp 120 to CD4. The 
peptide already synthesised, GC I, has been shown to mimic a discontinuous epitope 
with three of the amino acids present. To further expand this work, peptides were 
synthesised mimicking epitopes containing one and two of the necessary amino acids. 
Binding to CD4, and the ability to raise antibodies was studied. Selective removal of 
the important amino acids should lead to a reduction of binding of peptides to CD4, 
and antibodies raised to the native protein, gp 120. The peptides were analogues of 
GC  with one or both of the amino acids equating to Asp-457 or Asp-457 and Glu-





















The structure of the GC  analogues, showing the amino acids critical for CD4 binding 



















2.4.1 GO mono-Ala 
The peptide was synthesised on a 0.25 mmol scale using a single coupling method, 
with the triazole activated ester of the amino acid formed using DIC. The synthesis 
proceeded smoothly to give the coupling profile shown below (Figure 2.20). 
Figure 2.20 
Coupling profile of peptide GC 1 mono-Ala 
Cysteine was incorporated as the Acm derivative as before. Differing from the 
synthesis of GC 1, the Acm protected peptide was isolated using preparative HPLC. 
The Acm group was removed using silver trifiate and the cystine bond formed using 
2.5% DMSO in TFA. Analytical HPLC traces of the Acm protected, reduced and 
oxidised peptides are shown below (Figure 2.21). 
Once isolated, the peptide gave an amino acid analysis corresponding to the required 
peptide (see Figure 2.22), Ellmans assay gave a result of 0.00 free cysteines and the 
accurate mass spectrum was correct to within 0.32 ppm. 
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(a) 	 (b) 	 (c) 
Figure 2.21 
HPLC traces of (a) Acm protected, (b) reduced and (c) oxidised mono-Ala peptide 
Amino Acid Expected Found Amino Acid Expected Found 
Asx 3.00 2.99 Val 2.00 1.77 
Thr 3.00 2.72 Ile 2.00 1.63 
Ser 5.00 4.11 Leu 3.00 2.87 
GIx 1.00 0.96 Phe 	- 1.00 1.00 
Pro 1.00 1.05 His 1.00 0.92 
Gly 5.00 4.82 Lys 1.00 0.90 
Ala 1.00 1.19 Arg 1.00 1.27 
rcy-s 
2.00 1.01* 
Asx = Asp and Asn, Gix = Glu and Gin. *Cyeine  result is uncorrected for oxidative 
effects. 
Figure 2.22 
Amino acid analysis ofGCl mono-Ala 
68 
2.4.2. GO bis-Ala 
The above peptide was synthesised on a 0.25 mmol scale using a single coupling 
method, with the triazole activated ester of the amino acid formed using DIC. The 
synthesis proceeded relatively smoothly until the final two amino acids, when a large 
drop in coupling efficiency was observed, giving the profile shown below (Figure 
2.23). Upon cleavage and deprotection, a fairly large amount of unwanted products 
were present. This can be seen in the analytical HPLC of the crude Acm protected 
material (see Figure 2.24), and in the amino acid analysis of the resin which indicated 
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Figure 2.23 
Coupling profile of GC 1 bis-Ala 
Figure 2.24 




Due to the relatively disappointing synthesis ofGCl bis-Ala and the presence of lysine 
at the N terminus of the completed peptide, ion exchange chromatography was 
attempted. pH 9 was found to be the ideal conditions for separation of the required 
peptide from its deletions. Unfortunately, upon scale up, it was noted that the peptide 
was not sufficiently soluble, even at relatively low concentrations, in the buffer for this 
method to be used. Thfmoc separation in conjunction with porous graphitised carbon 
was also attempted in the same way as described for GC  in section 2.2.3, with little 
success. 
The Acm peptide was not separated, as for GC I. Removal of the Acm group was 
effected using the silver triflate method previously described (see section 2.3). Upon 
separation of the reduced peptide using HPLC, cystine formation was carried out 
using 2.5% DMSO in TFA, as for GC1. Upon separation of the peptide, the amino 
acid analysis and mass spectrum were in good agreement with expected results. 
Analytical HPLC showed the peptide to be >95% pure and Ellnians assay gave a 
result of 0.00 free cysteines, indicating correct oxidation (see Figure 2.25). 
Amino Acid Expected Found Amino Acid Expected Found 
Asx 3.00 2.73 Val 2.00 1.64 
Thr 3.00 2.74 lie 2.00 1.58 
Ser 5.00 4.13 Leu 3.00 2.99 
Pro 1.00 0.90 Phe 1.00 0.89 
Gly 5.00 4.85 His 1.00 0.91 
Ala 2.00 2.15 Lys 1.00 0.79 
Cys 2.00 0•57* Arg 1.00 1.01 
Gix = Glu and Gin. *cysteine result is uncorrected for oxidative effects. 











(c) Mass spectrum ofGCl bis-Ala (b) Analytical IIPLC ofGCl bis-Ala 
(showing thioglycerol adduct) 
Figure 2.25 
Data obtained on peptide GC  bis-Ala 
2.5 GC1 cyclopentyl derivative 
To understand the role of the Cys(378)-Val-Cys(445) turn in both the presentation of 
the correct discontinuous epitopes, and its effect on overall antigenicity, a peptide was 
synthesised without this turn. The Cys(378)-Val-Cys(445) turn was replaced with an 
entirely synthetic moiety, 3-aniinocyclopentane- 1-carboxylic acid. (see Figure 2.26). 
coo 
Figure 2.26 
cis- 3-Aininocyclopentane.. 1-carboxylic acid 
This structure is thought to act as a (3-turn mimic. The pseudo-diequatorial form of 
cis-aminopentane- 1-carboxylic acid is energetically favoured relative to the diaxial 
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interactions can lead to the diaxial form being favoured. The peptide in question was 
synthesised by repeating the work of Urquhart 2 , using the improved synthetic 
procedures to reduce aspartimide rearrangement. 
2.5.1 Synthesis of GC1.cyclopentyl 
The peptide was synthesised on a 0.25 mmol scale using a single coupliii'g method, 
with the triazole activated ester of the amino acid formed using DIC. Automated 
synthesis was used apart from the coupling of the cyclopentyl moiety, which was 
single coupled manually using four fold excess of the triazole activated ester. Fmoc 
deprotections were carried out using a solution of 20% piperidine in DMF buffered 




Coupling profile ofGCl.cyclopentyl 
The synthesis led to a relatively clean peptide upon cleavage and deprotection. Few 
truncations or deletions were seen and there was little asp artimide rearrangement. As 
the Cys(378)-Val-Cys(445) moiety has been replaced, isolation of the major peak by 
HPLC led to the required peptide. Data collected on the peptide was found to be 
consistent with that already synthesised (see Figure 2.28). 
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Amino Acid Expected Found Amino Acid Expected Found 
Asx 4.00 3.92 lie 2.00 1.67 
Thr 3.00 2.78 Leu 3.00 2.97 
Ser 5.00 4.23 Phe 1.00 0.88 
GIx 1.00 1.04 His 1.00 0.92 
Pro 1.00 0.75 Lys 1.00 0.90 
Gly 5.00 5.12 Arg 1.00 0.95 
Val 1.00 0.78 
Asx = Asp and Asn, GIx = Glu and Gln 






(b) Analytical HPLC 	 (c) Mass Spectrum 
Figure 2.28 
Data collected on GC 1. cyclopentyl 
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2.6 ff1 
Once peptides containing one, two and three of the amino acids necessary for high 
affinity binding had been synthesised, a peptide was designed to integrate the fourth 
amino acid. Using the ideas perfected in the synthesis ofGCl, a peptide was designed 
which could be formed linearly using solid phase peptide synthesis, but containing 
structural information allowing it to present both discontinuous and continuous 
epitopes. 
The GC 1 template afforded two potential strategies. Either the peptide containing the 
fourth amino acid could be attached to the ends of the (IC 1, either the C- or N-
terminus or, with a slight alteration, it could be hung from the centre between the two 
cysteines. The latter was attempted as this was thought to be more likely to give the 
discontinuous epitopes required. The sequence of the template (IC 1 was changed to 
accommodate this strategy, incorporating a second N-terminus located between the 
two cysteines, by substituting the valine of the turn with a lysine to give the structure 
shown in Figure 2.29. 
The extra amino acid was incorporated because of its involvement in high affinity 
binding89. However, this is not the only reason this area of gp 120 is of interest. The 
amino acid Trp-427 was shown by Olshevsky to be extremely important for binding. 
Lasky et a!87 also showed this, but seemed to find the whole region around Trp-427 
critical for interaction with CD4. Deletion of Trp-427 results in a significant decrease 
in binding, whereas deletion of twelve amino acids from the area in question led to a 
complete loss of binding. Other work has also shown that this area is involved in a 
conformational switch of the whole gp 120 molecule on moving from hydrophilic to a 
hydrophobic region, as happens when a virion encounters a cell surface 245 ' 246' 247 ' 248 . 
The region has been shown to have the potential to form both p3-sheet and a-helix 
structure and sharply switches between the two. This area seems to be extremely 
important in binding and post-binding events and thus it was deemed to be a useful 
area to study. 
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Sequence of IH1 showing the four amino acids 
critical for high affinity binding (boxed) 
(all numbers based on gp 120 from H1VifiB strain) 
To accomplish the synthesis, protection of the extra nitrogen of lysine needed to be 
orthogonal in relation to both base and acid, allowing selective deprotection when 
required. Hopp and Woods249 calculations carried out with the amino acids of GC 1 
(not shown) predicted a very hydrophobic area around the turn. I141 was based 
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closely on the structure of (IC 1. Thus, the cc-nitrogen was orthogonally protected and 
the peptide grown as normal from the Fmoc protected c-nitrogen to reduce the 
chances of folding of the peptide on the resin obscuring the second N-terminus. 
NH c-nitrogen 
a-nitrogen H3N Z 
0 
Figure 2.30 
The amino acid lysine 
2.6.1 Orthogonal lysine protection 
There are several orthogonal protecting groups available for use with lysine. Enzyme 
cleavable protection, such as the Phenac group already mentioned, is unsuitable in this 
instance due to the swelling problems of the Wang resin in the aqueous solution 
required. Photosensitive protecting groups such as 6-mtroveratryloxycarbonyl 
(NVOC) and 2-nitrobenzyloxycarbonyl (NBOC) 250 have been known for many years 
and have been used in varying ways, recently reviewed 251 . One of the most useful has 
been shown to be the Abc group first introduced for c-amino protection by Stevens 
and Watanabe 2.12  and later improved by Kunz253 and Crivici254 (see Figure 2.31(a)). 
Stable to both acids and bases, the Abc group can be removed using several different 
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(a) Abc protected 	 (b) Dde 	protected 
Figure 2.31 
N(e) protection of Lysine 
The Dde group259 was found to be most convenient for removal under solid phase 
conditions (see Figure 2.32(b)). Dde is orthogonal to both Fmoc and Boc protection. 
It is stable to repeated Fmoc deprotections using pip eridine, but is extremely labile 
using 2% v/v hydrazine in DMF, by the mechanism shown below (see Figure 2.32). 
The group is very versatile, with peptides containing Dde being used in template 
synthesis260 , in the synthesis of thepitopal multiple antigen peptides 261 and cyclic 
peptides262. The Dde group has also been used as a temporary protecting group 263, a 
useful property in relation to this research. The versatility and dependable nature of 
the group, together with its compatibility with solid phase synthesis, led to the groups 

















R( 1 ) 
Figure 2.32 
Deprotection of Dde with hydrazine 
2.6.2 Synthesis of 1111 
The peptide was synthesised on a 0.25 mmol scale using the single coupling method, 
with the triazole activated ester of the amino acid formed using DIC. The synthesis 
was carried out up to Cys-445 using normal automated synthesis. The Dde-Lys 
(Fmoc) OH was then manually coupled using four times excess of the activated 
triazole ester. This allowed expansion of the chain through the E-nitrogen, with the 
introduction of the new amino acid sequence containing the fourth important amino 
acid, again synthesised using automation. Lys-433 was introduced using Fmoc-Lys 
(Fmoc)OH. Upon coupling, the Fmoc was removed and the two free NH 2 groups 
were capped using acetic anhydride. The Dde group located on lysine was then 
removed, Cys-378 was then coupled using automated synthesis and the peptide 
assembly was completed by growing from the a-nitrogen. 
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The synthesis proceeded relatively well, with a slight drop after the manual coupling 
of Dde protected lysine (see Figure 2.33(a)). After completion of the linear peptide, 
the Dde group was removed and the branched peptide completed. The addition of the 
rest of the amino acid sequence proceeded smoothly, as can be seen from the coupling 
profile (Figure 2.33(b)) (NB, the coupling percentages for the second part of the 
peptide, in Figure 2.33(b) are calculated from lysine between Cys-378 and Cys-445, 
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(b) Coupling profile of second part of I141 
Figure 2.33 
1H  was isolated in a similar fashion to (IC 1. The main additional problem associated 
with 1111 was the presence of the amino acid methionine, which is prone to oxidation 
on cleavage and deprotection 264 '265 to form methionine sulfoxide. Cleavage and 
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deprotection of the completed peptide was carried out in the usual way, with a small 
amount of thioanisole added in an attempt to suppress any acid oxidation of the 
vulnerable 266 Analytical HPLC showed a reasonably clean peptide, with 
little of the oxidised product present (see Figure 2.34). 
-__-•-__ Q-  - 
Figure 2.34 
Analytical HPLC of crude IHi 
The Acm protected peptide was not isolated, but deprotected immediately. This was 
first attempted using silver triflate in TFA, as for GC I. Analytical HPLC traces of the 
subsequent product showed a clean reaction. However, the product became more 








Analytical HPLC of the removal of Acm from [Hi using the silver triflate I TFA 
procedure (a) Acm protected IH1, (b) ff11 after silver triflate / TFA procedure 
This shift to a shorter retention time indicated other reactions occurring at the same 
time as the Acm removal. Oxidation of methionine is known to lead to an increase in 
hydrophilic nature of the peptide due to the polarity of the S-O bond (see Figure 2.36) 
O Me 
0 	 0 
Figure 2.36 
Resonance structures of Met(0) 
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It seemed likely that the methionine was being oxidised during Acm removal. Further 
evidence of this was observed in the mass spectrum of the peptide, being 16 a.m.u. 
higher than that required for the reduced IH1. 
Acm removal was then attempted utilising mercuric acetate in 50% acetic acid / 
water211 , this weaker acid should diminish the methionine oxidation. The reaction was 
initially carried out in air, leading to removal of the -Acm groups, but relatively large 
amounts of oxidation was observed. Carrying out the deprotection under nitrogen 
reduced the amount of methionine oxidation in the above reaction, but it was still 
significant. Sonication of the acetic acid / water solution to remove dissolved oxygen, 
before its addition to the peptide, and a reduction in the amount of stirring given to 
the reaction, led to a great improvement in the amount of methionine oxidation (see 
Figure 2.39). 
Acm removed IH1, 
methionine sulfoxide 
Acm removed 11111 
(a) 	 (b) 
Figure 2.39 
(a) Removal of Acm with mercury acetate under air and (b) after somcating the 
solvent and under nitrogen 
Removal of the Acm protection allowed the isolation of the reduced peptide by 




successful method for formation of the bond in GC1 was with the use of DMSO in 
TFA. This gave short reaction times and good yield of the required product. 
Unfortunately, when attempting the same procedure with IH1, not only did cystine 
form, but the methionine was oxidised. 
An oxidation procedure was required mild enough to allow cystine formation without 
methionine oxidation. Cotton 218  attempted to use air oxidation with GC 1. but found 
the reaction slow and leading to side products. It was known that formation of the 
cystine bridge gives a characteristic peak shift with the reduced peptide eluting later 
than the oxidised. Air oxidation was attempted by dissolving the peptide in 50% 
acetonitrile / water and allowing to stand for several days. Analytical HPLC was used 
to follow the reaction. It was seen over time that most of the peak corresponding to 
the reduced peptide was converted to this new peak (see Figure 2.38). 
4 days 10 days 
Figure 2.38 
Monitoring Disulfide bond formation by HPLC 
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Preparative HPLC was used to separate the peak. Amino acid analysis gave results 
corresponding to the correct peptide, along with Elimans assay (expected = 0.00, 
obtained = 0.00) and mass spectrometry. Analytical HPLC showed >95% purity (see 
Figure 2.39) 
Amino Acid Expected Found Amino Acid Expected Found 
Asx 5.00 5.10 Met 1.00 TO 
Thr 3.00 2.93 Ile 3.00 2.93 
Ser 5.00 4.10 Leu 3.00 3.58 
GIx 4.00 3.91 Phe 2.00 1.69 
Pro 1.00 0.78 His 1.00 0.88 
Gly 7.00 7.30 Lys 3.00 2.57 
Cys 2.00 Ø•ØØ* Arg 1.00 1.02 
Val 2.00 1.70 
Asx = Asp and Asa, Clix = Glu and Gin. *Cyethe  result is uncorrected for oxidative 
effects. 
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(b) Analytical HPLC 	 (c) Mass Spectrum 
Figure 2.39 
Data obtained on the peptide IH1 
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2.6.3 Circular dichroism of peptide 1111 
Circular dichroism is a technique to measure the optical activity and hence probe the 
structure of asymmetrical molecules in solution. CD signals are observed in the same 
UV region where the absorption of particular chromophores are found. In CD, a 
peptide solution is exposed to plane polarised light. If the peptide contains structural 
elements in which the individual amino acids are arranged non-randoml then the 
light will be turned through an angle 9 relative to the polarisation of the incident light. 
This angle gives information on the said structural elements. In general, the more 
secondary structure a protein contains, the larger the angle 9 will be. 
CD bands in the amide region contain information about peptide bonds and secondary 
structure. The far UV CD spectra was determined for IH1 at the Scottish circular 
dichroism facility at Stirling University 267 . The secondary structure was then 
determined using the Contin secondary structure program 268, giving results as shown 
below 
Peptide 	 % cc-helix 	% 13-sheet 	% remaining 
1111 	 aqueous pH7 	3±0.5 	39±0.5 	58±1.0 
50% TFE 	38 ± 1.1 	29± 1.2 	33 ± 2.0 
The CD spectra obtained from I111 showed low levels of a-helical structure. Upon 
addition of trifluoroethanol, structure was induced corresponding to 38% a-helix, 
with only a relatively small reduction in the amount of 13-sheet present. The CD 













































































































































































































Note : In some of the following experiments serum obtained directly from the mice 
was used without further purification. In others, purified IgG was used. In each case, 
the experiment discussion makes clear which of the two was utilised. FM1I)V is a 
random peptide with 44 residues used in some of the following experiments as a 
negative control. 
2.7 Immunogenicity and Epitope Mapping Studies of if! 
Investigation of the immunogenic properties of the peptides was carried out. lOtg of 
purified GC1, (iCi mono-Ala, GC1 bis-Ala, (3C1.cyclopentyl or IH1 was injected 
interperitoneally into mice in Freund's adjuvant. Boost injections of lOtg of peptide in 
saline were carried out every three weeks until the maximum endpoint titre was seen. 
Blood was recovered and allowed to clot, with centrifugation then allowing the 
isolation of the immune serum. Peptide bound to 96 well microtitre ELISA plates was 
incubated with serial dilutions of anti-serum, or normal mouse serum. Bound 
antiserum was detected using horseradish peroxidase conjugated goat anti-mouse 
Ig(G,A,M) followed by o-phenylenediamine. The colouration reaction was stopped by 
the addition of 2N HC1 (50 pi) and the optical density (OD) of the wells read at 
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Titration of anti-I1-11 antiserum against ml. All values corrected for background 
absorbance of normal mouse serum at each dilution 
Epitope mapping studies investigated the presence of discontinuous epitopes on 
peptide ff11. Three linear peptides MRC 740-34 (KQSSGQDPEWTHSFNCGQE), 
MRC 740-42 (GQIRCSSNTTGLLTRDGQNS) and 1H2 (KQFTh4MWQEVG) were 
used to map the continuous epitopes contained within the peptide. Serial dilutions of 
purified anti-peptide IgG and purified normal mouse IgG were incubated with the 




















Comparison of antibody binding to peptide 1111 and linear peptides MKC 740-34 
(KQSSGGDPEIVTHSFNCGGE), MRC 740-42 (GQIRCS SNITGLLTRDGQNS) 
and 1112 (KQFINMWQEVG). All values corrected for background absorbance of 
normal mouse serum at each dilution 
From the above, when a mixture of equimolar amounts of linear peptides was 
incubated with the purified serum, the OD values obtained were significantly lower 
than those to 1111 itself These results show that component(s) of the IgG fraction 
recognise linear epitopes in both the C3 and C4 regions of gp 120, but not to the same 
extent as the peptide I111 is recognised. The peptide structure thus contains 
discontinuous epitiopes, analogous to peptide (3C1 218 . 
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GC 1 mono-Ala 	 • 1:5000 
GC  bis-Ala 1:10000 





Endpoint titres of anti-peptide sera against peptides 
Antiserum to peptide IH1 gives low cross binding. GC  produced high titres of anti-
peptide antibodies, confirming the results of Cotton et a1269. This study showed the 
presence of a high level of class switched antibodies pointing to the presence of both 
B- and T-cell epitopes. Immunisation with GC1.cyclopentyl has been shown to raise 
negligible amounts of anti-peptide antibodies. Thus it seems likely that the Cys(378)-
Val-Cys(445) turn is significant, either in presentation of the T-cell epitope, or 
residues in the turn are involved in the epitope itself with changes reducing the 
immunogenicity of the resultant peptide. 
As can be seen from the results of serial dilutions of serum raised to peptides (3€ 1 
mono-Ala and (IC 1 bis-Ala, the removal of the charged residues from the peptide also 
affects immunogenicity. It is known the peptides found to bind to the MIHC-I, the 
cellular protein used in the presentation of epitopes to T-lymphocytes, tend to be 
short peptides. These peptides are approximately eight to ten amino acids in length 
and generally contain charged residues 270 . It seems likely the removal of these charged 
amino acids in the mono and bis mutants would lead to disruption in binding of the T-
cell epitope present to the MHC-I, and hence affect the efficiency of the humoral 
response to the peptide. 
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2.9 Binding of serum raised against GC1 and ff1 to all peptides 
Peptide molarity (pM) 
(a) 	 (b) 
Figure 2.44 
Binding of peptides against a) (3C1 IgG (10pgIml), b) 1111 IgG (15pg/ml) (all values 
are corrected for background absorbance of normal mouse serum at each dilution. 
Error bars were removed for clarity, all standard deviations < 0. 1, n3) 
Antisera raised to GC 1 and ff11 were tested for their ability to bind other peptides in 
the series. It was observed that in both cases there was maximum binding of the 
peptide the sera it was raised against. However, 1111 also bound equally well to cx-
GC1 IgG as GC  itself; indicating IH1 has the ability to adopt conformations similar 
to those found in GC I. GC  was not as well recognised by a-IH1 IgG as IHi itself; 
suggesting there are epitopes present on IHi not present on GC1. All other peptides 
bound with reduced ability to both sera, due to the structural differences present. 
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2.10 Binding of ff1 to CD4 119 cells 
To demonstrate binding of 1111 to cells expressing CD4, IH1 or a random peptide 
FMDV were incubated with H9 cells (carried out by Dr. S.E.M Howie, Dept. of 
Pathology). Bound peptide was detected using either purified anti-GC1 IgG (shown 
to cross react with peptide 1111) or IgG from normal mouse serum, followed by 
incubation with phycoerythrin (PE) conjugated goat anti-mouse IgG. The +ve cells 
could then be visualised using the fluorescence of PE by flow cytometly. The results 
below (Figure 2.45) show binding of peptide at differing dilutions. Only in the 
presence of IH1 and anti-GC 1 IgG was binding seen. The results are shown 
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Figure 2.45 














400 	 200 	 100 
Peptide molarity (pM) 
Figure 2.46 
Binding of I41 and FMDV to CD4 H9 cells at different molarities (all values 
corrected for background absorbance of normal mouse IgG at each dilution) 
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Binding of peptides to (a) HeLa parent cell line, (b) HeLa cells transfected with CD4 
(all values are corrected for background absorbance of normal mouse IgG at each 
dilution, error bars are removed for clarity, all standard deviations <10%, n=6) 
It was shown above, IH1 is binding to CD4 H9 cells. Cotton et a1269 showed GC  
was binding to CD4 on the surface of cells. To demonstrate binding of 1111 and (IC 1 
variants to CD4, the peptides, along with the random peptide FMDV, were incubated 
with CD4 HeLa cells and HeLa cells transfected to express surface CD4 (performed 
by Dr. S.E.M Howie, Dept. of Pathology). As above, bound peptide was detected 
using either purified anti-CC 1 IgG or IgG from normal mouse serum, followed by 
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incubation with phycoerythrin (PE) conjugated goat anti-mouse IgG. It can be seen 
from the results above (Figure 2.47) that all peptides, except for the random peptide 
and 1111, bind to the CD4 transfected HeLa cells, but not to the parent cell line. The 
random peptide does not seem to bind to either cell lines. 1111 however, binds to the 
parent CD4 cell line as well as the CD4 transfected cells, but with greater affinity for 
the CD4 cell line. This indicates binding to CD4 as well as surface receptors other 
than CD4. 
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2.12 Binding of 1111 to an area of the cell surface proximate to CD4 
It had previously been shown that peptide GC  binds to HeLa cells transfected to 
express CD4 on the cellular surface, but not the parent cell line 269 . From the peptide 
binding studies to HeLa and CD4 HeLa cells, it was evident all peptides were 
interacting with the cellular surface through the receptor CD4 to a certain extent. To 
further prove H-Il was binding to the CD4 surface receptor, bound 11-Il was localised 
on the surface of cells using dual immunofluoroescence studies (carried out by M. 
Fernandes, Dept. of Pathology). CD4 MM6 (macrophage) cells were incubated with 
11-Il and then with antisera raised to the peptide GC I. Bound antisera was detected 
using TRJTC-labelled goat antimouse immunoglobulin. The cells were also incubated 
with biotinylated ct-CD4 IgG (MT3 10) and detected using FITC labelled avidin. Co-
localisation of colouration on the surface of the cell showed binding of the peptide 
IH1 to the cell surface in an area very close to the CD4 receptor. 
(a) 	 (b) 
Figure 2.48 
Binding of a) cc-GC I labelled with TRITC, b) a-CD4 labelled with FITC to cells pre- 
incubated with peptide IH1. Colouration shows both antibodies co-localised to the 
same region of the cell 
2.13 ff1 Binds to the CDR2 Region in Domain 1 of CD4 
The peptide 1111 and CD4 was shown to be co-localised on CD4 cells above. To 
conclusively demonstrate that 1111 binds to CD4 and to identify the region of CD4 
involved in the binding, JUl was used to block the interaction of antibodies 
recognising different regions of CD4 (carried out by M. Fernandes, Dept. of 
Pathology). The results below (Figure 2.49) show that pre-incubatioil of CD4 
expressing MM6 cells with Hi blocks subsequent binding of antibodies directed 
against domain 1, and in particular the CDR2 region of CD4 (Q4120), but not 
antibodies against other regions such as domain 4 (L120). ff11 is binding to CD4, 
using the same area of the CD4 molecule as gp120, the CDR2 region, which itself 









Q4120 	 L120 
Anti-CD4 mAb 
Figure 2.49 
Binding of cc-CD4 immunoglobulins showing blocking of Q4120, an antibody binding 
to domain 1 of CD4, but not L120, binding to domain 4 on the surface of MM6 cells 
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2.14 Peptide inhibition of MIP-1a binding 
Studies above (Section 2.11, Figure 2.47) indicated binding of peptide 1111 to the 
CD4 parent HeLa cell line. This unexpected result led to an attempt to pinpoint the 
alternate binding site. HeLa cells were known to express flisin on the cellular surface, 
the chemokine receptor shown to be involved in HIV fusion as a secondary co-
receptor for T-cell tropic viruses 149 . Due to a lack of suitable reagents, the binding of 
1111 to the fusin chemokine receptor could not be proven. CD4 H9 cells were shown 
to express CC-CKR5 on its surface, the chemokine receptor known to act as a 
secondary co-receptor for macrophage-tropic HIV' 57"58"59"60"6 ' This chemokine 
receptor, CC-CKR5, is known to bind the chemokine MP-la strongly and thus the 
possible interaction of the peptide 1111 with CC-CKR5 could be probed using the 
available photolabelled MIP- la reagent (R&D Systems, Europe Ltd.) (performed by 
M. Fernandes, Dept. of Pathology). 
Before initiating the experiment, the hydrophobicity of the N-terminal areas of the 
chemokines MTP-la, MIP-10 and RANTES known to bind to this receptor were 
compared with areas of IH1 using Hopp and Woods plots. 
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Amino acid sequence 
Figure 2.50 
Hopp and Woods plot of the N-termini of MIP-ia, MIP-i, 
RANTES and [Hi (424-432) 
The similarity in the hydrophobicity values for 1111 with those of the N-termini of the 
chemokine showed IH1 could interact with the chemokine receptor CC-CKR5. To 
demonstrate the validity of this argument, the binding of photolabelled MJP-ia to its 
receptor in the presence of 1111 was studied. Cells were pre-incubated with the 
peptides at 0.0 1mM, and treated with the labelled M1IP- ia. Reduction of binding of 
the chemokine would indicate peptide interaction with a surface component intimately 
involved with the chemokine binding site. MIP- ia binding was visualised using flow 
cytometry (see figure 2.53), giving the results shown below (figures 2.51) and 
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Figure 2.51 
Binding ofphotolabelled NIP- la to H9 cells after pre-incubation with 1) GC  mono- 
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Figure 2.53 
Inhibition of MIP- lix binding with IH1, but not with peptide FMDV, pictured using 
flow cytometry 
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It can be seen from the results in Figure 2.52 that Hi blocked interaction of MIP- la 
with its receptor to the greatest extent. Further experiments were then attempted 
using both MM6 (macrophage) and H9 (T cell) and Hi at different concentrations, 
to give the inhibition of MEP-la binding results as shown in Figure 2.54. Pre-
incubation with 1111 led to a reduction in the amount of photolabelled MP-la for 
both cell lines, with a negligible link with concentration at the concentrations used. 
Figure 2.54 
Inhibition of MEN ia binding by pre-incubation of [Hi with a) TvlM6 (macrophage 
cell line), and b) H9 (T cell line) 
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2.15 Induction of apoptosis 
The role of cross linked CD4 with a-CD4 immunoglobulins in the Fas driven 
apoptosis pathway is well documented 69. It has been proposed that the progressive 
depletion of CD4 cells in HIV infection is also due to this upregulation of Fas 
induced by cross linking with gp 120 and host a-gp 120 immunoglobulin. Work by 
Cotton27 ' has shown (IC1 and ct-GC1 IgG can cause apoptosis in the CD4 H9 cell 
line. The ability of peptide 1111 to induce apoptosis was investigated (performed by 
Dr. S.E.M Howie, Dept. of Pathology). The poor immunogenicity of the peptide led 
to the use of cc-GC I IgG, having previously shown recognition of IH1 using the said 
immunoglobulin, indicating the ability to cross link CD4 in the presence of bound 
peptide. Plates were coated with a-GC 1 IgG or normal mouse IgG and H9 cells pre-
incubated with peptide 1111 and a random peptide, FMDV, were added to the plate. 
Apoptosis was counted visually using a Lietz optical microscope. The results (figure 
















Apoptosis induced in the presence of IH1 and ct-GC1 IgG 
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Chapter 3 : Experimental 
3.1 Notes 
All amino acids were purchased from Bachem, except Dde-Lys(Fmoc)OH purchased 
from Novabiochem, and are of the L configuration. Dimethylformamide, 1,4-dioxane 
and piperidine were peptide synthesis grade and supplied by Rathburn 2hemicals. 
Acetic anhydride, DMAP and HOBt were obtained from Aldrich. Peptide synthesis 
grade TFA was obtained from ABI. All other solvents were distilled before use. UV 
absorption spectra were recorded on a Varian Cary 210 spectrophotometer or a 
Perkin Elmer Lambda 11 in the indicated solvent. Somcation of solutions and resins 
were performed with a Decon FS300b sonic bath. Fast atom bombardment mass 
spectra (FAB), both high and low resolution, were measured on a Kratos MS50TC 
machine using thioglycerol matrix. Amino acid analysis was performed on a LKB 
4151 alpha plus or a Pharmacia Biotech Biochrom 20 after Carius tube hydrolysis 
with constant boiling HC1 at 110°C for the indicated time. Circular dichroism spectra 
were recorded on a JASCO J600 spectropolarimeter with the indicated path length 
and solvent. ELISA were performed on a 96-well Costar EIA / RIA microtitre plates 
and the optical densities measured using a Dynatech MRS 000 microplate reader. 
Flourescence measurements in flow cytometly were measured on a Coulter EPICS 
CS machine. In apoptosis experiments, cells were counted with a Lietz UV optical 
microscope. Gel filtration and ion exchange chromatography were performed using 
Pharmacia / LKB columns under the stated conditions together with two LKB 2138 
IJVICORDS (X = 226 and 277 nn), a Pharmacia 2132 Microperpex peristaltic pump, 
an LKB 2112 redirac fraction collector and a Pharmacia GM gradient mixer. High 
performance liquid chromatography (HPLC) was carried out on one of two systems: 
an ABI 1783A programmable detector, two ABI 140A units for solvent delivery and 
an ABI 1480A injector, or a Gilson 305 control pump, a Gilson 306 slave pump, an 
ABI 785A programmable detector and a Gilson 811C dynamic mixer. The HPLC 
columns and gradients are given in the text. 
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3.2 Solid Phase Peptide Synthesis 
All peptides were synthesised using amino acids N  protected using the 9-
Fluorenylniethoxycarbonyl (Fmoc) group, with orthogonal, acid labile protection for 
side chains where necessary, and an acid labile peptide-resin linker as described in the 
text. Where more than one side chain protection is available, the text clarifies the one 
used. 
3.2.1 Preparation of Fmoc-amino acid resins 
A solution of Fmoc-amino acid (3.52mmol) and N,N'-diisopropylcarbodiimide (DIC, 
1. 86mmol) in the minimum DMF (6m1) was sonicated for 15 mm. This solution was 
then added to p-benzyloxybenzyl alcohol (Wang) resin (flinctionalised at 0.88mmolIg, 
ig, 0.88mmol) pre-swollen with Sml DMF and treated with 4-(N,N'-dimethylamino)-
pyridine (DMAP, 30mg, 0.2mmol). The mixture was then sonicated for 1.5hr. The 
sonication time was varied depending upon the required level of substitution. The 
resin was collected by filtration, washed thoroughly with DMF, Dioxane and diethyl 
ether and dried in vacuo to yield the Fmoc-amino acid resin. 
3.2.2 Determination of loading of Fmoc-amino acid resin 
Samples of the thoroughly dried resin (1-3mg) were accurately weighed and added to 
a solution of 20% piperidune in DMF (lOmi). The solution was then somcated for 20 
min. The UV absorbance of the solution was then measured at A=302 urn and the 
concentration of the piperidine-fulvene adduct calculated using the Beer-Lambert 
Law, with the extinction coefficient of the adduct as 15,400dm 3mor'cm 1 . The resin 
substitution could then be calculated from these values. 
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3.2.3 Automated Solid Phase Peptide Synthesis 
All syntheses of peptides described used the following method of chain assembly. All 
the peptides were synthesised on an Applied Biosynthesis 430A automated peptide 
synthesiser fitted with an Applied Biosystems 757 UV monitoring system linked to a 
Hewlett Packard HP3396A integrator, allowing real time monitoring of coupling 
efficiencies. The syntheses were carried out on either 0.25 or 0.5 mmol scale'. 
Each amino acid cycle involved three basic steps, carried out in the following order. 
capping any unreacted amino groups. 
deprotection of the base labile cc-amino terminus. 
coupling of the next protected amino acid. 
Each step of the cycle was followed by washing, and the cycle repeated until the 
required peptide sequence was obtained. 
Capping 
The resin was vortexed for 10 mm. with a solution (lOml) containing acetic anhydride 
(0.5mol), DIEA (0. 125mo1) and HOBt (0.2%w/v) in a 1:1 solution of DMF/dioxane. 
The capping solution was drained and the resin washed in a 1:1 solution of 
DMF/dioxane (5 x 8m1). 
Deprotection 
Each deprotection cycle consisted of three deprotections, the resin vortexed with a 
solution of 20% piperidine in a 1:1 solution of DMF/dioxane (lOmi) for 6, 1.5 and 1.5 
mm. Part of the deprotection solution was run to a UV monitor to allow real time 
assessment of coupling. Between these deprotections, the resin was washed with a 1:1 
solution of DMF/dioxane (4 x 8ml). After the three deprotections, the resin was 
washed with a 1:1 solution of DMF/dioxane (8 x 8m1). 
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3) Coupling 
This was carried out using double coupling with the HOBt activated ester, or single or 
double coupling using the triazole activated ester as described below. 
Double coupling with HOBt activated ester 
The initial coupling step utilised the symmetrical anhydride of the amino acid. The 
resin (0.25mmol) was vortexed with a solution of Fmoc amino acid p're-formed 
symmetrical anhydride (0.5mmol,, formed from lmmol Fmoc amino acid and 0.5mmol 
DIC reacted for 30 min in the activator vessel) for 30 mm. The solution was removed 
and the resin washed with a 1:1 solution of DMF/dioxane (7 x 8m1). The resin was 
vortexed for a further 30 min with the Fmoc amino acid HOBt activated ester 
(0.5mmol, formed from 0.5mmol Fmoc amino acid, 0.5mmol HOBt and 0.5mmol 
DIC), drained and washed with a 1:1 solution of DMF/dioxane (7 x 8m1). 
The exceptions to the above were asp aragine, glutamine and histidine, which were 
coupled twice using their HOBt ester (0. 5mmol, formed as above). Glycine was 
coupled singly as its symmetrical anhydride (0.5mmol, formed as above). 
Single or double coupling with triazole activated ester 
Single coupling - The resin (0.25mmol) was vortexed for 30 mm. with a solution of 
pre-formed Fmoc amino acid triazole active ester (immol, formed from lmmol Fmoc 
amino acid, immol triazole and 1 mmol DIC, reacted for 20mm.) before being drained 
and washed with a 1:1 solution of DMF/dioxane (7 x 8m1). 
Double coupling - The resin (0.25mmol) was vortexed for 30 mm. with a solution of 
pre-formed Fmoc amino acid triazole active ester (lmmol, formed from immol Fmoc 
amino acid, Immol triazole and immol DIC, reacted for 20mm.) before being drained 
and washed with a 1:1 solution of DMF/dioxane (7 x 8m1). The resin was then 
vortexed for a second period (30mm.) with a further amount of Fmoc amino acid 
triazole ester (immol., formed as above). The solution was drained and the resin 
washed with a 1:1 solution of DMF/dioxane (7 x 8m1). 
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3.2.4 Ellnian's assay for free thiol groups 
Quantitative Ellman's assa?72 enables the number of free thiol groups per molecule to 
be calculated. Accurately weighed peptide (0.02-0.05pmol) was dissolved in 
denaturing buffer consisting of 0. 1M sodium phosphate buffer pH 7.3 (2.5m1), 
containing EDTA (0.01M) and GdmCl (6M). A fresh solution of 5.5'-dithiobis-(2-
nitrobenzoic acid), (DTNB, 3mM) in sodium phosphate buffer pH 7.3 wasprepared. 
Denaturing buffer (2.5m1) was placed in the reference cell and denaturing buffer plus 
peptide placed in the sample cell of a UV spectrometer. DTNB solution (lOOpl) was 
added to each cell and mixed by inversion and left to stand for 5 mm. The absorbance 
at 412nm was then recorded. The concentration of free thiols can then be calculated 
using the Beer-Lambert Law, with the extinction coefficient of the nitrothiobenzoate 
(NTB) formed being 13700M 1 cm 1 at 412nm in 6M GdmCl. 
3.2.5 Initial acid cleavage of resin bound peptide 
The scavenger mix specified in the text was added to dry peptide resin (5 0mg) and the 
mixture stirred for 5 min under nitrogen. The stated amount of TFA was then added 
ant the mixture stirred at room temperature under nitrogen. Samples of the 
deprotection solution (approx. 0.5m1) were removed periodically and concentrated in 
vacuo. The resulting residues were triturated with diethyl ether and the peptides 
collected by filtration. The peptide was washed with diethyl ether, dissolved in 20% 
acetic acid / water and analysed by HPLC. The optimum cleavage conditions were 
identified and scaled up to 200-400mg batches of peptide resin. 
3.2.6 Attempted TMS Bromide deprotection of GC1 Cys-Acm 
Resin bound peptide (200mg) was stirred at 0°C under nitrogen with EDT ( 500pi), 
m-cresol (100t1) and thioarnsole (1. 17ml) for 5 mm. TFA (7.5m1) was then added and 
the whole stirred for a further 10 mm. TMS bromide (1.32m1) was added and the 
whole stirred for 3 hr. The resin was removed by filtration and washed with TFA. The 
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TFA was then reduced in vacuo. The peptide was triturated with diethyl ether 
(100m!) and collected by filtration, dissolved in acetic acid in water (100m!) and 
lyophilised to yield 85 mg of crude white solid. Analytical HPLC (Aquapore C18, 
220x4.6mni, 7p.m, lOOjil loop, A = 1120, B = CH3CN, 0.1% TFA; 1 ml/min . 10-90% 
B over 35 mm. ? = 214) gave a collection of products, which were difficult to 
separate. 
3.2.7 Tbfnioc labelling of GC1 derivatives 
Thfmoc chloride (50mg, 0. l2mmol) was taken and dissolved in the minimum of 
dioxane (6m1). Resin bound peptide, with the terminal Fmoc protecting group 
removed (0.1 lmmollg, 200mg, 0.022mmol) along with DIEA (3.t1, 0.025mmol) was 
then added. The mixture was somcated in the dark for 2.5 hr and the resin thoroughly 
washed with dioxane (50m1, with somcation) and the resin dried in vacuo. A small 
portion of the Thflnoc labelled resin (2.7mg) was then suspended in 20% piperidine in 
DMF and the solution sonicated for 20 mm. The UV absorbance of the solution was 
then measured at X=364 nm (2.68 Abs) and the concentration of the piperidine adduct 
calculated using the Beer-Lambert law, knowing the extinction coefficient. The resin 
substitution could then be calculated from these values (0. 12mmol/g). The percentage 
loading of the Thfmoc group could then be calculated (approximately 40%). 
Resin bound peptide (310mg) was stirred at room temperature under nitrogen with 
EDT (2ml) and water (lml) for 5 mm. TFA (lOmi) was then added and the whole 
stirred for a further 4 hr. The resin was then removed by filtration and washed with 
TFA. The TFA was then reduced in vacuo. The peptide was then triturated with 
diethyl ether (lOOml) and left to stand over ether for 1 hr before being collected by 
filtration, dissolved in acetic acid in water (100m!) and lyophilised to yield 136 mg of 
crude white solid. 
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3.3 Peptide GC1 (KSSGGDPELVTIISFNCR2SSN1TGLLLTRDGG) : Cysteme 
protected by Phenacm group. 
3.3.1 Synthesis of bis-Phenacm GC1 
Fmoc-Gly resin (0.66mmoIIg, 0.38g, 0.25mmol) was formed as above. Cysteine was 
protected on the side chain as the Phenacm derivative 27', aspartic acid as the t-butyl 
ester derivative, arginine as the Pmc derivative, threonine as the t-butyl ether 
derivative, serine as the t-butyl ether derivative, glutamic acid as the t-butyl ester 
derivative, histidine as the trityl derivative and lysine as the Boc protected derivative. 
Asp aragine was coupled unprotected on the side chain. All other amino acids were 
unprotected on the side chain. The synthesis was carried out on a 0.25mmol scale. 
Each amino acid was double coupled using initially the Fmoc amino acid symmetrical 
anhydride (0.5mmol, formed from immol Fmoc amino acid and 0.5mmol DIC in the 
activator vessel) followed by the Fmoc amino acid HOBt activated ester (0. 5mmol,, 
formed from 0.5mmol Fmoc amino acid, 0.5mmol HOBt and 0.5mmol DIC During 
the Na deprotection, HOBt (0. 1M) was present in the 1:1 solution of DMF/dioxane 
containing 20% piperidine. Amino acid analysis of the completed resin (24 hr 
hydrolysis) gave values as below. 
Asx4 2.89, Tkr3 2.56, Ser5 2.98, G1x 1 0.92, Pro 1 1. 13, G1y5 5.13, Cys2 0.12, Va12 1.67, 
11e2 1.70, Leu3 2.82, Phe 1 0.87, His 1 0.90, Lys i 0.76, Arg i 1.00 
3.3.2 Cleavage and deprotection of bis-Phenacm protected GC1 from the resin 
Resin bound peptide (286mg) was stirred at room temperature under nitrogen with 
EDT (0.5m1) and water (0.5m1) for 5 mm. TFA (9.5m1) was added and the whole 
stirred for a further 4 hr. The resin was removed by filtration and washed with TFA. 
The TFA was then reduced in vacuo. The peptide was triturated with diethyl ether 
(lOOmI). The peptide was collected by filtration, dissolved in acetic acid in water 
(lOOmi) and lyophilised to yield 135 mg of crude white solid. The recovered peptide 
was gel filtered (G50 Sephadex, 30% acetic acid in water, 30 ml/hr) and the required 
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fractions combined and lyophilised to give 55mg of white solid. Analytical HPLC 
(Vydac C18, 250x4.6mm, 5p.M, 2m1 loop, A = H20, B = CH3CN, 0.1% TFA; 1 
ml/min. 10-90% B over 35 mm. ?. = 214) gave a major peak, retention time 21.9 min., 
60%B. The Phenac protected peptide was then isolated using preparative HPLC 
(Vydac C18, 250x22mm, 10tm, 5m1 loop, A = 1120, B = CH3CN, 0.1% TFA; 
9m1/min., 10-60 0/oB in 30 mm. 
14mg of the title compound was isolated. Analytical HPLC (Vydac C18, 250x4.6mm, 
5pm, lOOp.il loop, A = H20, B = CH3CN, 0.1% TFA; lml/min. 10-90% B over 35 
mm. X = 214) showed >95% purity; retention time 17 mm., 49%B; m/z 3560.67859 
(FAB), C 154H242N42051S2 requires 3560.71092; deviation = -9.90 ppni Amino acid 
analysis (26 hr hydrolysis) gave values as below. 
Asx4 3.85, Thr3 2.63, Ser5 4.03, G1x1 1.25, Pro 1 1.54, Gly5 5.03, Cys2 1.58, Va12 2.17, 
11e2 1.59, Leu3 3.17, Phe 1 1.03, His, 0.97, Lys i 0.98, Arg i 0.99. 
3.3.3 Attempted enzyme removal of Phenacm group 
GC1 Cys-Phenacm protected, from above (2.2mg, 0.6pmol) was taken and dissolved 
in ammonium acetate buffer (pH 8.5m1). A small amount of resin bound penicillin 
acylase (30mg) was added to the solution and the whole shaken at 37°C. Small 
portions of the solution were removed periodically and analysed by analytical HPLC 
(Vydac C18, 250x4.6mm, 5pm, 100tl loop, A = H20, B = CH3CN, 0.1% TFA; 
imI/min. 10-90% B over 35 mm. ?. = 214). The desired removal of the Phenac group 
was not seen even after 14 days. 
3.3.4 Attempted mercuric acetate removal of Phenacm group from bis-Phenacm 
protected GC1 
GC1-Phenacm protected, from above (5mg, 1.4p.mol) was dissolved in 30% acetic 
acid in water (2ml) and treated with 50 equivalents of mercury acetate (2.24mg, 
7mmol) and the pH adjusted to 4. The whole was stirred in the dark for 24 hr. The 
solution was lyophilised and the resultant solid dissolved in GdnCl (6M, lOmi). 200 
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equivalents of dithiothreitol (DTT, 43mg, 0.28mmol) and the whole stirred for 24 hr 
in the dark Small portions of the solution were removed periodically and analysed by 
analytical HPLC (Vydac C18, 250x4.6mm, 5p.m, lOOp.l loop, A = H20, B = CH3CN, 
0.1% TFA; imI/min. 10-90% B over 35 mm. X = 214). The white suspension of 
mercury / DTT salt was removed by filtration and the resultant solution lyophilised. 
After addition of a few drops of water to the resultant white suspension, the solution 
was gel filtered (G50 Sephadex, 30% acetic acid in water, 30m1/hr) and the desired 
fractions lyophilised to yield 2.2mg of white solid. Analytical HPLC (Vydac C18, 
250x4.6mni, Sum,  Sml loop, A = H20, B = CH3CN, 0.1% TFA; 1 ml/min . 10-90% B 
over 35 mm. X = 214) gave a major peak at retention time 28.7 mm, %B=75.5. The 
peak gave a mass consistent with mercury salt of (iCi; m/z (laser desorption) 3464, 
C 136H224N40049S2Hg requires 3466. 
3.3.5 Attempted silver trifluoromethanesulfonate removal of Phenacm group 
formation of GC1 reduced 
Phenacm protected GC1 above (10mg, 0.003mmol) was stirred at 4°C with TFA 
(5m1) and twenty equivalents of silver triflate (25mg, 0.1 immol) for 2 hr in the dark. 
The TFA was removed in vacuo and the silver salt of the peptide triturated with 
diethyl ether. The salt was dissolved in 50% acetic acid in water (4ml) and treated in 
the dark overnight at room temperature with 100 equivalents of DTT (56mg, 
0.36mmol). The solution was diluted with water (6m1) and centrifuged (5000 rpm, 30 
mm). After centrifugation, the supernatant was decanted from the yellow pellet. The 
pellet was then washed with 20% acetic acid in water (Sml) and the supernatant 
collected after further centrifugation. The supernatants were combined. Analytical 
HPLC (Vydac C18, 250x4.6mm, 5gm, 100l loop, A = H20, B = CH3CN, 0.1% 
TFA; lmllmin. 10-90% B over 35 min. X = 214) gave a major peak, retention time 
17.5 mm., 50%B; The reduced peptide was then isolated using preparative HPLC 
(Vydac C18, 250x22mm, lOim, Sm! loop, A = H20, B = CH3CN, 0.1% TFA; 9 
ml/min. Linear gradient 10%B for 10 mm, 10-60%B in 30 mm. The desired fractions 
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lyophilised to yield 2.4mg of the title compound as a white solid, found to be the 
reduced form ofGCl, mlz (FAB) 3265 C 136H224N40049S2 requires 3265. 
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3.4 Peptide GC1 (KSSGGDPEIVTLISFNCVCSSNITGLLLTRDGG) 
Optimised synthesis 
3.4.1 Synthesis of bis-Acm GC1 
Fmoc-Gly resin (0.41nimollg, 1.2g. 0.5mmol) was formed as above. Cysteine was 
protected on the side chain as the Acm derivative, aspartic acid as the t-butyl ester 
derivative, arginine as the Pmc derivative, threonine as the t-butyl ether derivative, 
asparagine as the trityl derivative, serine as the t-butyl ether derivative, glutamic acid 
as the t-butyl ester derivative, histidine as the trityl protected derivative and lysine as 
the Boc protected derivative. All other amino acids were unprotected on the side 
chain. The synthesis was carried out on a 0. 5mmol scale. Each amino acid was double 
coupled using the Fmoc amino acid triazole activated ester (immol per coupling, 
formed from lmmol Fmoc amino acid, lmmol tnazole and lmmol DIC) as described 
above, except for histidine which was single coupled twice as the HOBt activated 
ester. During the Na deprotection, HOBt (0. 1M) was present in the 1: 1 solution of 
DMF/dioxane containing 20% piperidine. Amino acid analysis of the completed resin 
(24 hr hydrolysis) gave values as below. 
Asx4 3.07, Tbr3 2.40, Ser5 3.30, G1x1 0.78, Pro 1 1. 15, G1y5 4.89, Cys2 0.23, Va!2 1.19, 
11e2 1.40, Leu3 2.73, Phe 1 0.77, His 1 0.78, Lys, 0.87, Arg 1 0.94 
3.4.2 Cleavage and deprotection of bis Acm protected GC1 from the resin 
Resin bound peptide (310mg) was stirred at room temperature under nitrogen with 
EDT (2m1) and water (lml) for 5 mm. TFA (lOml) was added and the whole stirred 
for a further 4 hr. The resin was removed by filtration and washed with TFA. The 
TFA was then reduced in vacuo. The peptide was triturated with diethyl ether 
(lOOmI) and left to stand over ether for 1 hr. The peptide was collected by filtration, 
dissolved in acetic acid in water (lOOml) and lyophilised to yield 136mg of crude 
white solid. Analytical HPLC (Vydac C18, 250x4.6mm, 5iM, 100.tl loop, A = H 20, 
B = C143CN, 0.1% TFA; 1 ml/min. 10-90% B over 35 mm. X = 214) gave a major 
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peak, retention time 14.0 mm., 42%B; m/z (laser desorption) 3408.3, 
C 142H233N4205 1 S2 requires 3408.9. 
3.4.3 Removal of Acm groups from crude bis-Acm protected peptide GC1 
formation of Gd. reduced 
Crude cleaved Acm protected Gd! above (50mg, approximately O.OlnImol) was 
stirred at 4°C with TFA (5m1) and silver triflate (75mg, 0.3mmol) for 2 hr in the dark. 
The TFA was removed in vacuo and the silver salt of the peptide triturated with 
diethyl ether. The salt was dissolved in 50% acetic acid in water (lOml) and treated in 
the dark overnight at room temperature with DTT (23 0mg, 1.45mmol). The solution 
was diluted with water (lOmi) and centrifuged (5000rpm, 30mm). After 
centrifugation, the supernatant was decanted from the yellow pellet. The pellet was 
then washed with 20% acetic acid in water and the supernatant collected after further 
centrifugation. The supernatants were combined. Analytical HPLC (Vydac C 18, 
250x4.6nim, 5i.Lm,  100tl loop, A = H20, B = CH3CN, 0.1% TFA; imI/min. 10-90% 
B over 35 mm. ?. = 214) gave a major peak, retention time 14.7 mm., 43.5%B; The 
reduced peptide was then isolated using preparative HPLC (Vydac C18, 250x22mm, 
1O.tm, 5m1 loop, A = H20, B = CH3CN, 0.1% TFA; 9mllmin. Linear gradient l0%B 
for 10 mm, 10-37%B in 27 min., 37-42%B in 10 mm. Three peaks were isolated and 
the appropriate fractions were lyophilised. 
Peak 1: GC I. reduced 
17mg of the title compound isolated. Analytical HPLC (Vydac C18, 250x4.6mm, 
5p.m, 100.tl loop, A = H20, B = CH3CN, 0.1% TFA; lml/min. 10-90% B over 35 
mm. X = 214) showed >95% purity; retention time 14.4 mm., 43%B; mlz 3266.55776 
(FAB), C 136H224N40049S2 requires 3266.57409; deviation = -5.00 ppm. Quantitative 
Ellman's assay gave a value of 1.58 (2.00) sulfhydryl groups per molecule. Amino acid 
analysis (26 hr hydrolysis) gave values as below. 
Asx4 4.14, Thr3 3.06, Ser5 4.70, G1x1 1.03, Pro 1 1.30, G1y5 5.00, Cys2 1. 13, Va12 1.70, 
11e2 1.60, Leu3 3.09, Phe l 0.98, His 1 1.05, Lys 1 1.28, Arg i 1. 17. 
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Peak 2: GC I . reduced, aspartimide rearranged 
4.1mg of the title compound isolated. Analytical HPLC (Vydac C18, 250x4.6mm, 
5pm, lOOjil loop, A = H20, B = CH3CN, 0.1% TFA; lml/mn. 10-90% B over 35 
mm. X = 214) retention time 15.3 min., 45%B; m/z 3248.54652 (FAB), 
C 136H222N40048S2 requires 3248.56352; deviation = 5.24 ppm. Quantitative E11min's 
assay gave a value of 0.73 (2.00) sulfhydiyl groups per molecule. Amino acid analysis 
(26 hr hydrolysis) gave values as below. 
Asx4 3.52, Thr3 2.67, Ser5 4.27, G1x 1 1.06, Pro 1 1.00, G1y5 5.09, Cys2 0.15, Va12 1.65, 
11e2 1.62, Leu3 3.07, Phe 1 0.9 1, His 1 0.98, Lys, 1.23, Arg i 1.11. 
Peak 3 : GC 1 . reduced, piperidide rearranged 
1.0mg of the title compound isolated. Analytical HPLC (Vydac C18, 250x4.6mni, 
5pm, 100.tl loop, A = H20, B = CH3CN, 0.1% TFA; imI/mun. 10-90% B over 35 
min. X = 214) retention time 15.8 mm., 46%B; mlz 3333.66800 (FAB), 
C 141H233N41048S2 requires 3333.65267; deviation = 4.60 ppm.  Quantitative Ellnian's 
assay gave a value of 0.98 (2.00) sulfhydryl groups per molecule. 
3.4.4 Oxidation of GC1. reduced: Formation of GC1 
Pure reduced GC1 (10.7mg, 3.3p.mol) was taken and stirred at room temperature 
with 2.5% DMSO in TFA (lOmI) for 45 mm. The TFA was reduced in vacuo and the 
peptide triturated with diethyl ether. The peptide was then collected by filtration and 
dissolved in acetic acid / water. Analytical HPLC (Vydac C18, 250x4.6mm, 5pm, 
lOOp.l loop, A = H20, B = CH3CN, 0.1% TFA; imI/min. 10-90% B over 35 mm. ?s. = 
214) showed >95% purity, retention time 14.4 mm., 43%B. Analytical HPLC 
(Hichrom C18, 250x4.6mm, 5jtm, 100d loop, A = H20, B = CH3CN, 0.1% TFA; 
lmllmin. 10-90% B over 35 min. ?. = 214) showed two peaks present. 
The oxidised peptide was purified using preparative HPLC (Aquapore C18, 
250x9.2mm, 10pm, 5m1 loop, A = H20, B = CH3CN, 0.1% TFA; 5m1/min, 10-90%B 
in 30 min). The peak was isolated and the appropriate fraction lyophilised to yield 4.6 
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mg of the title compound. Analytical HPLC (Hichrom C18, 250x4.6mm, 5i.im,  lOOitl 
loop, A = H20, B = CH3CN, 0.1% TFA; imI/min. 10-90% B over 35 mm. ?. = 214) 
showed >95% purity; retention time 14.9 mm., 44%B. in/z 3263.54122 (FAB), 
C 136H222N40049 S2 requires 3263.55508; deviation = 4.25 ppm. Quantitative Ellman's 
assay gave a value of 0.00 (0.00) sulthydryl groups per molecule. Amino acid analysis 
(25 hr hydrolysis) gave values as below. 
Asx4 4.18, Thr3 3.18, Ser5 4.67, G1x1 0.98, Pro 1 0.92, G1y5 5.22, Cys2 0.67, 'Va!2 1.79, 
11e2 1.66, Leu3 3.29, Phe 1 0.98, His, 1. 11, Lys, 1.38, Arg i 1.12. 
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3.5 Peptide GC1 mono-Ma (KSSGGDPEIVTILSFNCVCSSNITGLLLTRAGG) 
3.5.1 Synthesis of bis-Acm GC1 mono-Ma 
Fmoc-Gly resin (0.566mmo1/g, 440mg, 0.25mmol) was formed as above. Cysteine 
was protected on the side chain as the Acm derivative, aspartic acid as the t-butyl 
ester derivative, arginine as the Pmc derivative, threonine as the t-btyl ether 
derivative, asparagine as the trityl derivative, serine as the t-butyl ether derivative, 
glutamic acid as the t-butyl ester derivative, histidine as the trityl protected derivative 
and lysine as the Boc protected derivative. All other amino acids were unprotected on 
the side chain. The synthesis was carried out on a 0.25mmol scale. Each amino acid 
was single coupled using the Fmoc amino acid triazole activated ester (immol per 
coupling, formed from immol Fmoc amino acid, lmmol tnazole and immol DIC) as 
described above, except for histidine which was single coupled as the HOBt activated 
ester. Amino acid analysis of the completed resin (26 hr hydrolysis) gave values as 
below. 
Asx3 2.6 1, Thr3 3.14, Ser5 3.59, G1x 1 0.93, Pro 1 1.29, G1y5 4.63, Ala 1 1.37, Cys2 0.47, 
Va12 1.65, 11e2 1.68, Leu3 3.15, Phe 1 0.88, His 1 1.00, Lys i 0.74, Arg i 1.33 
3.5.2 Cleavage and deprotection of his Acm protected GC1 mono-Ma from the 
resin 
Resin bound peptide (65mg) was stirred at room temperature under nitrogen with 
EDT (imI) and water (lml) for 5 mm. TFA (lOmi) was added and the whole stirred 
for a further 4 hr. The resin was removed by filtration and washed with TFA. The 
TFA was then reduced in vacuo. The peptide was triturated with diethyl ether 
(1 OOml). The peptide was collected by filtration, dissolved in acetic acid in water 
(lOOml) and lyophilised to yield 40 mg of crude white solid. The Acm protected 
peptide was isolated using preparative HPLC (Vydac C18, 250x22mm, 10pm, 5m1 
loop, A = H20, B = CH3CN, 0.1% TFA; 9mllmin., linear gradient l0%B for 10 mm, 
10-55%B in 30 mm). 
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3.5 Peptide GC1 mono-Ma (KSSGGDPEIVTBSFNCVCSSN1TGLLLTRAGG) 
3.5.1 Synthesis of bis-Acm, mono-Ma GC1 
Fmoc-gly resin (0.566mmo1/g, 440mg, 0.25mmol) was formed as above. Cysteine was 
protected on the side chain as the Acm derivative, aspartic acid as the t-butyl ester 
derivative, arginine as the PMC derivative, threonine as the t-butyl ether aerivative, 
asparagine as the tntyl derivative, serine as the t-butyl ether derivative, glutamic acid 
as the t-butyl ester derivative, histidine as the trityl protected derivative and lysine as 
the Boc protected derivative. All other amino acids were unprotected on the side 
chain. The synthesis was carried out on a 0.25mmol scale. Each amino acid was single 
coupled using the Fmoc amino acid triazole activated ester (lmmol per coupling, 
formed from immol Fmoc amino acid, lmmol triazole and immol DIC) as described 
above, except for histidine which was single coupled as the HOBt activated ester. 
Amino acid analysis of the completed resin (26 hr hydrolysis) gave values as below. 
Asx3 2.61, Thr3 3.14, Ser5 3.59, G1x1 0.93, Pro 1 1.29, G1y5 4.63, Ala 1 1.37, Cys2 0.47, 
Vat2 1.65, 11e2 1.68, Leu3 3.15, Phe 1 0.88, His 1 1.00, Lys i 0.74, Arg i 1.33 
3.5.2 Cleavage and deprotection of his Acm protected mono-Ma GC1 from the 
resin 
Resin bound peptide (65mg) was stirred at room temperature under nitrogen with 
EDT (imI) and water (imi) for 5 mm. TFA (lOmi) was added and the whole stirred 
for a further 4 hr. The resin was removed by filtration and washed with TFA. The 
TFA was then reduced in vacuo. The peptide was triturated with diethyl ether 
(lOOmi). The peptide was collected by filtration, dissolved in acetic acid in water 
(lOOml) and lyophilised to yield 40 mg of crude white solid. The Acm protected 
peptide was isolated using preparative I{PLC (Vydac C18, 250x22mm, 10tm, 5m1 
loop, A = H20, B = CH3CN, 0.1% TFA; 9m1/min., linear gradient 10%B for 10 mm, 
10-55%B in 30 mm. 
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4.6 mg of the title compound was isolated. Analytical HPLC (Vydac C18, 
250x4.6mni, 5j.tm, 5m1 loop, A = H20, B = CH3CN, 0.1% TFA; lml/mun. 10-90% B 
over 35 min. X = 214) showed >95% purity; retention time 20.8 min., 57.5%B; m/z 
3364.67435 (FAB), C 141H 4N42049S2 requires 3364.65849; deviation = 4.77 ppm. 
Amino acid analysis (24 hr hydrolysis) gave values as below. 
Asx3 2.89, Thr3 3.08, Ser5 4.64, G1x1 1.00, Pro 1 0.98, G1y5 4.84, Ala 1 1. 13, Cys2 1.2 1, 
Va12 1.65, lie2 1.55, Leu3 2.98, Phe 1 1.00, His1 1.00, Lys, 0.96, Arg 1 1.02 * 
3.5.3 Removal of Acm groups from bis-Acm protected peptide GC1 mono-Ala: 
formation of GC1 mono-Ala. reduced 
Bis Acm protected GC  mono-Ala above (15mg, 0.004mmol) was stirred at 4°C with 
TFA (5m1) and twenty equivalents of silver triflate (22.7mg, 0. lOmmol) for 2 hr. in 
the dark. The TFA was removed in vacuo and the silver salt of the peptide triturated 
with diethyl ether. The salt was dissolved in 50% acetic acid in water (4m1) and 
treated in the dark overnight at room temperature with 100 equivalents of DTT 
(69mg, 0.44mmol). The solution was diluted with water (6ml) and centrifuged 
(5000rpm, 30mm). After centrifugation, the supernatant was decanted from the 
yellow pellet. The pellet was then washed with 20% acetic acid in water (5m1) and the 
supernatant collected after further centrifugation. The supernatants were combined. 
The reduced peptide was then isolated using preparative HPLC (Vydac C18, 
250x22mni, 10tm, 5m1 loop, A = H20, B = C113CN, 0.1% TFA; 9m1/min. Linear 
gradient 10%B for 10 mm, 10-55%B in 45 min). The desired fractions were 
lyophilised to yield 3.9mg of the title compound as a white solid. Analytical HPLC 
(Vydac C18, 250x4.6mm, Spin, 5m1 loop, A = H20, B = CH3CN, 0.1% TFA; 1 
ml/min. 10-90% B over 35 mm. X = 214) showed >95% purity; retention time 22.3 
min., 61%B; m/z (FAB) 322 1.58694 C 135H223N40047 S2 requires 322 1.57643 deviation 
3.26 ppm. Amino acid analysis (25 hr hydrolysis) gave values as below. 
Asx3 2.98, Thr3 3.03, Ser5 4.60, G1x 1 1.00, Pro 1 0.88, G1y5 4.90, Ala, 1. 10, Cys2 1.65, 
Va12 1.78, lIe2 1.61, Leu3 2.91, Phe 1 0.98, His 1 1.00, Lys i 0.94, Arg 1 1.03 
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3.5.4 Oxidation of GC1 mono-Ma, reduced: Formation of GC1 mono-Ma 
Pure reduced (IC1 mono-Ala (5mg, 1.6tmol) was taken and stirred at room 
temperature with 2.5% DMSO in TFA (5m1) for 40 mm. The TFA was reduced in 
vacuo and the peptide triturated with diethyl ether. The peptide was collected by 
filtration, dissolved in acetic acid / water and lyophilised. The peptide was then re-
lyophilised from acetonitrile / water to yield 4.6mg of the title compound Is a white 
solid. Analytical HPLC (Vydac C18, 250x4.6mm, 5pm, Sml loop, A = 11 20, B = 
CH3CN, 0.1% TFA; lml/min. 10-90% B over 35 mm. X = 214) showed >95% purity, 
retention time 20.6 mm., 57%B. m/z 3220.56756 (FAB), C 135H222N40047 S2 requires 
3220.56861; deviation = 0.32 ppm. Quantitative Ellman's assay gave a value of 0.00 
(0.00) sulfhydryl groups per molecule. Amino acid analysis (26 hr hydrolysis) gave 
values as below. 
Asx3 2.99, Thr3 2.72, Ser5 4.11, G1x 1 0.96, Pro 1 1.05, G1y5 4.82, Ala 1 1.19, Cys2 1.01, 
Va12 1.77, 11e2 1.62, Leu3 2.87, Phe 1 1.00, His 0.92, Lys i 0.90, Argi 1.27 
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3.6 Peptide GC1 bis-Ala (KSSGGDPA1VTHSFNCVCSSNITGLLLTRAGG) 
3.6.1 Synthesis of bis-Acm GC1 bis-Ala 
Fmoc-Gly resin (0.72mmol/g, 350mg, 0.25mmol) was formed as above. Cysteine was 
protected on the side chain as the Acm derivative, aspartic acid as the t-butyl ester 
derivative, arginme as the Pmc derivative, threonine as the t-butyl ether derivative, 
asparagine as the trityl derivative, serine as the t-butyl ether derivative, histidine as the 
trityl protected derivative and lysine as the Boc protected derivative. All other amino 
acids were unprotected on the side chain. The synthesis was carried out on a 
0.25mmol scale. Each amino acid was single coupled using the Fmoc amino acid 
triazole activated ester (lmmol per coupling, formed from lmmol Fmoc amino acid, 
immol triazole and lmmol DIC) as described above, except for histidine which was 
single coupled as the HOBt activated ester. Amino acid analysis of the completed 
resin (27 hr hydrolysis) gave values as below. 
Asx3 2.3 3, Thr3 2.72, Ser5 3.64, Pro  1. 08, Glys 4.90, Ala2 2. 10, Cys2 0.69, Va12 1.4 1, 
11e2 1.44, Leu3 2.87, Phe 1 0.85, His 1 0.89, Lys i 0.49, Arg i 1.06 
3.6.2 Cleavage and deprotection of bis Acm protected GC1 bis-Ala from the 
resin 
Resin bound peptide (330mg) was stirred at room temperature under nitrogen with 
EDT (2m1) and water (lml) for 5 mm. TFA (lOmi) was added and the whole stirred 
for a further 4 hr. The resin was removed by filtration and washed with TFA. The 
TFA was then reduced in vacuo. The peptide was triturated with diethyl ether 
(1 OOml). The peptide was collected by filtration, dissolved in acetic acid in water 
(lOOml) and lyophilised to yield 179mg of crude white solid. Analytical HPLC (Vydac 
C18, 250x4.6mm, 5p.m, lOOtl loop, A = H20, B = CH3CN, 0.1% TFA; imI/min. 10-
90% B over 35 mm. ? = 214); major peak retention time 17.70 mm., 50.5%B. 
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3.6.3 Removal of Acm groups from crude bis-Acm protected peptide GC1 bis-
Ala : formation of GC1 bis-Ala. reduced 
Crude bis Acm protected GC1 bis-Ala above (40mg, approx. 0.01mmol) was stirred 
at 4°C with TFA (5m1) and twenty equivalents of silver triflate (60mg, 0.28mmol) for 
2 hr in the dark The TFA was removed in vacuo and the silver salt of the peptide 
triturated with diethyl ether. The salt was dissolved in 50% acetic acid in water (4m1) 
and treated in the dark overnight at room temperature with 100 equivalents of DTT 
(180mg, 1.2mmol). The solution was diluted with water (lOml) and centrifuged 
(5000rpm, 30mm). After centrifugation, the supernatant was decanted from the 
yellow pellet. The pellet was then washed with 20% acetic acid in water (SmI) and the 
supernatant collected after further centrifugation. The supernatants were combined. 
The reduced peptide was then isolated using preparative HPLC (Vydac C18, 
250x22mm, 10im,, Sm! loop, A = H20, B = CH3CN, 0.1% TFA; 9m1/min. Linear 
gradient 10%B for 10 mm, 10-55%B in 45 mm). The desired fractions were 
lyophilised to yield 3.5mg of the title compound as a white solid. Analytical HPLC 
(Vydac C18, 250x4.6mm, Spin, Sm! loop, A = H20, B = C143CN, 0.1% TFA; 
imI/min. 10-90% B over 35 mm. ?. = 214) showed >95% purity; retention time 21.7 
mm., 59.5%B; m/z (FAB) 3164.58188 C 133H222N40045S2 requires 3164.57878 
deviation 0.98ppm. Quantitative Ellman's assay gave a value of 1.34 (2.00) sulfhydryl 
groups per molecule. Amino acid analysis (24 hr hydrolysis) gave values as below. 
Asx3 2.63, Thr3 2.94, Ser5 4.50, Pro 1 0.86, G1y5 4.95, Ala2 2.05, Cys2 0.00, Va12 1.73, 
lie2 1.56, Leu3 3.05, Phe 1 0.97, His 1 0.94, Lys i 0.85, Arg i 1.15 
3.6.4 Oxidation of GC1 bis-Ala. reduced: Formation of GC1 bis-Ala 
Pure reduced GC  bis-Ala (6mg, 1.6p.mol) was taken and stirred at room temperature 
with 2.5% DMSO in TFA (6m1) for 40 mm. The TFA was reduced in vacuo and the 
peptide triturated with diethyl ether. The peptide was collected by filtration, dissolved 
in acetic acid I water and lyophilised. The peptide was then re-lyophilised from 
acetonitrile / water to yield 5.78mg of the title compound as a white solid. Analytical 
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HPLC (Vydac C18, 250x4.6mm, 5tm, 5m1 loop, A= H20, B = CH3CN, 0.1% TFA; 
imI/min. 10-90% B over 35 mm. A. = 214) showed >95% purity, retention time 21.2 
mm., 58.5%B. m/z 3163.56217 (FAB), C 133H221N40045S2 requires 3163.57095; 
deviation = 2.78 ppm. Quantitative EUmlin's assay gave a value of 0.00 (0.00) 
sulfhydiyl groups per molecule. Amino acid analysis (26 hr hydrolysis) gave values as 
below. 
Asx3 2.73, Thr3 2.74, Ser5 4.13, Pro 1 0.90, G1y5 4.85, Ala2 2.15, Cys2 0.57, Va12 1.64, 
11e2 1.58, Leu3 2.99, Phe i 0.89, His1 0.91, Lys 1 0.79, Arg i 1.01 
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3.7 Peptide GC1.cyclopentyl, incorporating cis-3-ammocyclopentane-1-
carboxylic acid (acpc) (KSSGGDPE1VTUSFN(acpc)SSNITGLLLTRDGG) 
3.7.1 Synthesis of GC1.cyclopentyl 
Fmoc-Gly resin (0.54mmoI/g, 460mg, 0.25mmol) was formed as above. Aspartic acid 
was protected on the side chain as the t-butyl ester derivative, arginine ag the Pmc 
derivative, threonine as the t-butyl ether derivative, asparagine as the trityl derivative, 
serine as the t-butyl ether derivative, glutamic acid as the t-butyl ester derivative, 
histidine as the trityl protected derivative and lysine as the Boc protected derivative. 
All other amino acids were unprotected on the side chain. The synthesis was carried 
out on a 0.25mmol scale. Each amino acid, apart from the central cyclopentyl moiety 
was single coupled using automation, utilising the Fmoc amino acid tnazole activated 
ester (immol per coupling, formed from immol Fmoc amino acid, lmmol triazole and 
immol DIC) as described above, except for histidine which was single coupled as the 
HOBt activated ester. The peptide was completed up to the cyclopentyl moiety 274 in 
the usual way. The terminal Fmoc was removed and cyclopentyl moiety manually 
coupled as the Fmoc triazole activated ester derivative (solution of immol, formed 
from lmmol cyclopentyl derivative, immol tnazole and lmmol DIC). The solution 
was somcated with the resin for 1 hr. The resin was then washed thoroughly and the 
synthesis completed automatically. Amino acid analysis of the completed resin (26 hr 
hydrolysis) gave values as below. 
Asx4 3.40, Thr 2.67, Ser5 3.82, Pro 1 0.91, Gly5 4.92, Va!1 1.22, 11e2 1.70, Leu3 3.21, 
Phe 1 1.07, His, 0.98, Lys i 0.97, Arg i 1.11 
3.7.2 Cleavage and deprotection of GC1. cyclopentyl peptide from the resin 
Resin bound peptide (300mg) was stirred at room temperature under nitrogen with 
EDT (2m1) and water (lml) for 5 mm. TFA (lOml) was added and the whole stirred 
for a further 4 hr. The resin was removed by filtration and washed with TFA. The 
TFA was then reduced in vacuo. The peptide was triturated with diethyl ether 
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(1 OOml), collected by filtration, dissolved in acetic acid in water (1 00m1) and 
lyophilised to yield 140mg of crude white solid. 100mg of the above crude cleaved 
peptide was then taken and the peptide isolated using preparative HPLC (Aquapore 
C18, 250x9.2mm, 10pm, 5ml loop, A = H20, B = CH3CN, 0.1% TFA; 5m1/min, 10-
55%B in 30 mm). The desired fractions were lyophilised to yield 35mg of the title 
compound as a white solid. Analytical HPLC (Hichrom C18, 250x4.6mm, 5p.ni, 
100t1 loop, A = H20, B = CH3CN, 0.1% TFA; lmI/min. 10-90% B over 3 mm. ?. = 
214) showed >95% purity; retention time 14 mm., 42%B; m/z (FAB) 3071.56578 
C 131H213N38047S2requires 3071.54789 deviation 5.82ppm. Amino acid analysis (24 hr 
hydrolysis) gave values as below. 
Asx4 3.92, Thr3 2.78, Ser5 4.23, Pro 1 1.04, G1y5 5.12, Val1 0.78, 11e2 1.67, Leu3 2.97, 
Phe 1 0.88, His 1 0.92, Lys, 0.90, Arg 1 0.95 
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3.8 Peptide ff1 (KSSGGDPE1VTHSFN&2SSN1TGLLLTRDGG) 
(KQF1T44MWQEVG) 
3.8.1 Synthesis of bis-Acm ff1 
Fmoc-Gly resin (0.53mmolIg, 0.49g, 0.25mmol) was formed as above. Cysteine was 
protected on the side chain as the Acm derivative, aspartic acid as the t-butyl ester 
derivative, arginine as the Pmc derivative, threonine as the t-butyl ether derivative, 
asparagine as the trityl derivative, glutamine as the trityl derivative, tryptophan as the 
Boc derivative, serine as the t-butyl ether derivative, glutamic acid as the t-butyl ester 
derivative, histidine as the tntyl protected derivative. Three orthogonal lysine 
derivatives were utilised, as described below. All other amino acids were unprotected 
on the side chain. The synthesis was carried out on a 0.25mmol scale. Each amino 
acid was double coupled using the Fmoc amino acid triazole activated ester (lmmol 
per coupling, formed from immol Fmoc amino acid, immol triazole and immol DIC) 
as described above, except for histidine which was single coupled twice as the HOBt 
activated ester and the orthogonal lysine derivative described below. During the Na 
deprotection, HOBt (0. IM) was present in the solution of 20% piperidine in 1:1 
DMF/dioxane. 
KCSSNITGLLLTRDGG 
The above peptide was synthesised using automated solid phase peptide synthesis in 
the usual way, described above. The underlined lysine above, located between the two 
cysteines was coupled as the N(Dde)-N(Fmoc) derivative. This was manually single 
coupled as the Fmoc triazole activated ester derivative (solution of immol, formed 
from immol lysine derivative, Immol triazole and immol DIC). The solution was 
sonicated with the resin for 1 hr. The resin was then washed thoroughly with DMF 
and Dioxane and dried in vacuo. A small amount of resin (2.8mg) was taken and a 




The peptide was continued after coupling of the lysine derivative, the chain being 
grown from the N- free amine using automated solid phase peptide synthesis in the 
usual way to yield the above peptide. The N-terminal lysine was coupled as the 
Na(Fmoc)W(Fmoc) derivative. Upon completion of coupling, the Fmoc groups were 
removed using a solution of 1:1 DMIF/dioxane containing 20% piperidine, ith 0. 1M 
HOBt present in the usual way. The free amine groups were acylated using a solution 
(lOmi) containing acetic anhydride (0.5mol), DIEA (0. 125mo1) and HOBt (0.2 0/ow/v) 
in a solution of 1:1 DMF/dioxane. The resin was vortexed for 10 min then the capping 




The Dde group present on the underlined lysine was removed by somcation of the 
resin with a solution of 2% hydrazine in DMF (1 Omi) for 20 mm. The solution was 
then removed and the resin washed with DMF(lOOml) and dioxane (lOOmi). To 
ensure the removal of the Dde group, a qualitative Kaiser test was used to indicate the 
presence of free primary amines. A small sample of peptide resin was removed and 
placed in a vial. Three solutions were added consecutively. Firstly, ninhydrin in 
ethanol (5%w:v, 75tl) was added followed by phenol in ethanol (400 1/ow:v, lOOp.l). 
Finally a solution of aqueous KCN (1mM) in distilled pyridine (2 0/ov:v, 75j.il) was 
added and the vial heated for 5 min at 110°C. A positive test was indicated by a blue 
colouration. The peptide was then completed by coupling to the free a amine group 
using automated solid phase peptide synthesis in the usual way to yield the above 
peptide. 
Amino acid analysis of the completed resin (32 hr hydrolysis) gave values as below. 
Asxs 4.72, Thr3 3.52, Ser5 3.89, G1x4 2.93, Pro 1 0.87, Gly7 7.33, Cys2 0.76, Va12 1.52, 
Met 1 0.61, lie3 2.51, Leu3 4.43, Phe2  1.68, His1 0.95, Lys3 2.32, Arg i 1.48 
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3.8.2 Cleavage and deprotection of peptide Lilt from the resin 
Resin bound peptide (300mg) was stirred at room temperature under nitrogen with 
EDT (2m1), thioanisole (500pL) and water (imi) for 5 min. TFA (lOmi) was added 
and the whole stirred for a further 4 hr. The resin was removed by filtration and 
washed with TFA. The TFA was then reduced in vacuo. The peptide was triturated 
with diethyl ether (100m!) and left to stand over ether for 1 hr. The pe'ptide was 
collected by filtration, dissolved in acetic acid in water (1 OOml) and lyophilised to 
yield 130mg of crude white solid. 20mg of the above crude peptide was taken and the 
Acm protected peptide isolated using preparative HPLC (Vydac C18, 250x22mm, 
10.tm, Sm! loop, A = H20, B = C113CN, 0.1% TFA; 9m1/min., 10-30 0/oB in 10 min, 
30-50%Bin20min. 
Analytical HPLC (Vydac C18, 250x4.6mm, 5pm, 100tl loop, A = H20, B = CH3CN, 
0.1% TFA; imI/min. 10-90% B over 35 mm. X = 214) showed >95% purity; retention 
time 16 mm., 46.5%B; m/z 4897.39078 (FAB), C 210H333N60049S3 requires 
4897.36222; deviation = 5.83ppm. 
3.8.3 Attempted silver trifluoromethanesulfonate removal of the Acm group 
Crude Acm protected 1111 above (50mg, approximately 0.0lmmol) was stirred at 4°C 
with TFA (5m1) and thirty equivalents of silver triflate (75mg, 0.33mmol) for 2 hr in 
the dark. The TFA was removed in vacuo and the silver salt of the peptide triturated 
with diethyl ether. The salt was dissolved in 50% acetic acid in water (4m1) and 
treated in the dark overnight at room temperature with 150 equivalents of DTT 
(230mg, 1.5 mmol). The solution was diluted with water (6m1) and centrifuged 
(5000rpm, 30mm). After centrifugation, the supernatant was decanted from the 
yellow pellet. The pellet was then washed with 20% acetic acid in water (5m!) and the 
supernatant collected after further centrifugation. The supernatants were combined. 
The major peak was then isolated using preparative HPLC (Vydac C18, 250x22mm, 
l0tm, Sm! loop, A = H20, B = CH3CN, 0.1% TFA; 9m1/min. Linear gradient lO%B 
for 10 mm, 10-30%B in 10 mm, 30-50%B in 20 mm). The desired fractions were 
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lyophilised to yield 4.5mg of white solid. Analytical HPLC (Vydac C18, 250x4.6mm, 
5jtm, 5m1 loop, A = H20, B = CH3CN, 0.1% TFA; ml/min . 10-90% B over 35 mm. X 
214) showed >95% purity; retention time 15.1 mm., 44.5%B; m/z (FAB) 4769 
C20411322N58058S3 (I111, Acm removed, with methionine sulfoxide) requires 4769. 
Quantitative Eliman's assay gave a value of 1.76 (2.00) sulfhydiyl groups per 
molecule. 
3.8.4 Mercuric acetate removal of Acm groups : formation of 1111. reduced 
Crude Acm protected 1111 above (50mg, approximately 0.Olmmol) was taken and 
dissolved in 50% acetic acid in water (2m1), this solution having been previously 
somcated to remove any dissolved gases, and mercury acetate (12mg, 0.04mmol) 
added. The whole was stirred slowly under nitrogen at room temperature for 1 hr. 
DTT (100mg, 0.67mmol) was added and the whole stirred for a further 1.5 hr. The 
solution was diluted with water (lOmi) and centrifuged (5000rpm, 30mm). After 
centrifugation, the supernatant was decanted from the grey/white pellet. The pellet 
was then washed with 20% acetic acid in water (Sml) and the supernatant collected 
after further centrifugation. The supernatants were combined. The reduced peptide 
was isolated using preparative HPLC (Vydac C18, 250x22mm, l0tm, 5m1 loop, A = 
H20, B = CH3CN, 0.1% TFA; 9m1/min. Linear gradient 10-35%B in 20 mm, 35-
50%B in 20 mm). The desired fractions were lyophilised to yield 6.9mg of the title 
compound as a white solid. Analytical HPLC (Hichrom C18, 250x4.6mm, 5im, 
lOOpi loop, A = H20, B = CH3CN, 0.1% TFA; imI/min. 10-90% B over 35 mm. ? = 
214) showed >95% purity; retention time 17.1 mm., 49%B; mlz (FAB) 4756 
C204H326N58067 S3 requires 4756. Quantitative Ellman's assay gave a value of 1.60 
(2.00) sulihydryl groups per molecule. Amino acid analysis (31 hr hydrolysis) gave 
values as below. 
Asx5 5.29, T11r3 3.20, Ser5 4.43, G1x4 4.10, Pro  0. 92, Gly7 7.25, Cys2 0.23, Val2 1.82, 
Met, 0.42, LIe3 2.65, Leu3 3.37, Phe2 1.75, His, 0.95, Lys3 2.68, Arg i 0.90 
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3.8.5 Attempted oxidation of if!. reduced using DMSO / TFA 
Pure reduced 1111(3.5mg, 0.7pmol) was taken and stirred at room temperature with 
2.5% DMSO in TFA (3.5m1) for 50 min. The TFA was reduced in vacuo and the 
peptide triturated with diethyl ether. The peptide was then collected by filtration and 
dissolved in acetic acid / water. Analytical HPLC (Vydac C18, 250x4.6mni, 5pm, 
lOOp! loop, A = H20, B = CH3CN, 0.1% TFA; imI/min. 10-90% B over 35' min. ) 
214) gave a major peak at retention time 14.4 mm., 43%B, corresponding to a 
methionine sulfoxide peptide. Quantitative E11mn's assay gave a value of 0.00 (2.00) 
sulfliydiyl groups per molecule. This oxidation method also oxidised methionine to 
methionune sulfoxide as well as cystine oxidation. 
3.8.6 Attempted N-methyl-mercaptoacetamide (MMA) reduction of methionune 
sulfoxide present in ff1 
1111 methionune sulfoxide (0.5mg, 0. 1pmol) was taken and dissolved in 10% acetic 
acid in water (500pl). MMA (0.11mg, 0. ipI, 1. 1pmol) was added and the solution 
incubated under nitrogen at 37°C for 5 days. Small portions of the solution were 
removed periodically and analysed by analytical HPLC (Vydac C18, 250x4.6mm, 
5pm, lOOj.tl loop, A = H20, B = CH3CN, 0.1% TFA; imI/min. 10-90% B over 35 
mm. X = 214). It was seen that the reaction was not giving quantitative reduction of 
the methionine sulfoxide. This method was abandoned. 
3.8.7 Air oxidation of ff1. reduced 
Pure reduced HE (10mg, 2.2pmol) was taken and dissolved in 50% acetonitrile in 
water (150p1) and left to stand for 7 days. The solution was then lyophilised to yield a 
white peptide. This was dissolved in 20% acetonitrile in water (lOmi) and the oxidised 
peptide isolated using preparative HPLC (Aquapore C18, 250x9.2mni, 10pm, 5ml 
loop, A = H20, B = C143CN, 0.1% TFA; 5m1/min, 10-50%B in 40 mm). The desired 
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fractions were lyophilised to yield 5.6 mg of the title compound as a white solid. 
Analytical HPLC (Hichrom C18, 250x4.6mni, 5,im, 100tl loop, A = H20, B = 
CH3CN, 0.1% TFA; lmI/min. 10-90% B over 35 mm. A.. = 214) showed >95% purity; 
retention time 16.8 mm., 48.5%B; m/z (FAB) 4756.30508 C 204H324N58067 S3 requires 
4756.29581 deviation 1.95ppm. Quantitative Ellman's assay gave a value of 0.00 
(2.00) sulfliydryl groups per molecule. Amino acid analysis (32 hr hydrolysis) gave 
values as below. 
Asx5 5. 10, Thr3 2.93, Ser5 4.10, G1x4 3.91, Pro 1 0.78, G1y7 7.30, Cys2 0.00, Val2 1.70, 
Met 1 0.65, 11e3 2.93, Leu3 3.58, Phe2 1.69, His 1 0.88, Lys3 2.57, Arg i 1.02 
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3.9 Peptide KQF1NMWQEVG: peptide ffl2 
3.9.1 Synthesis of 1112 
Fmoc-Gly resin (0.52mmol/g, 480mg, 0.25mmol) was formed as above. Asparagine 
was protected as the trityl derivative, glutamine as the trityl derivative, tryptophan as 
the Boc derivative, serine as the t-butyl ether derivative, glutamic acid as the t-butyl 
ester derivative, and lysine as the Boc protected derivative. All other amino acids 
were unprotected on the side chain. The synthesis was carried out on a 0.25mmol 
scale. Each amino acid was single coupled using the Fmoc amino acid triazole 
activated ester (immol per coupling, formed from immol Fmoc amino acid, lmmol 
triazole and immol DIC) as described above. Amino acid analysis of the completed 
resin (24 hr hydrolysis) gave values as below. 
Asx 1 0.89, Glx3 3.76, Glyi 1.08, Va1 1 1.00, Met 1 0.54, 11e 1 0.89, Phe 1 0.92, Lys, 0.90 
3.9.2 Cleavage and deprotection of peptide 1112 from the resin 
Resin bound peptide (100mg) was stirred at room temperature under nitrogen with 
EDT (2ml), thioanisole (500pl) and water (imi) for 5 mm. TFA (lOmi) was added 
and the whole stirred for a further 3 hr. The resin was removed by filtration and 
washed with TFA. The TFA was then reduced in vacuo. The peptide was triturated 
with diethyl ether (lOOml), collected by filtration, dissolved in acetic acid in water 
(lOOmI) and lyophilised to yield 61mg of crude white solid. 20mg of the above crude 
cleaved peptide was then taken and the peptide isolated using preparative HPLC 
(Aquapore C18, 250x9.2mm, l0.im, 5m1 loop, A = H20, B = CH3CN, 0.1% TFA; 
Smllmin, 10-35%B in 20 mm). The desired fractions were lyophilised to yield 5.5 mg 
of the title compound as a white solid. Analytical HPLC (Hichrom C18, 250x4.6mm, 
5p.m, lOOjtl loop, A = H20, B = CH3CN, 0.1% TFA; lml/min. 10-90% B over 35 
mm. X = 214) showed >95% purity; retention time 11.6 mm., 36.5%B; m/z (FAB) 
1380.67920 C63H96N 16017 S 1 requires 1380.68601 deviation -4.90ppni Amino acid 
analysis (25 hr hydrolysis) gave values as below. 
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Asx 1 1.03, G1x3 2.93, G!y i 1.07, Va! 1 0.95, Met 1 0.64, 11e 1 0.93, Phe 1 0.93, Lys, 0.93 
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3.10 Immunisation with peptides 
Groups of five female BALB/C mice, 10 weeks old were immunised mtraperitoneally 
with the peptide (10p.g per injection in lOOp.! solution). The first injection was 
administered in either Freunds adjuvant or alum, followed by four further injections at 
three to four week intervals of peptide in PBS. 
3.11 Immunogenicity of peptides 
96-well Costar ELA/RIA microtitre plates were coated either overnight at 4°C, or for 
2-3 hr at room temperature with peptide (1 p.g/ml, 0.1 p.g per well) in 0.1 M 
carbonate/bicarbonate buffer pH 9.6. The plate was then washed three times with 
phosphate buffered saline (PBS) containing 0.05% v:v Tween 20. Blocking was 
achieved by incubating with a solution of 1% m:v bovine serum albumen (BSA) in 
PBS for 1 hr at room temperature. After three further washes as described above, 
serially diluted serum (100 p.1 per well, diluted with 1% m:v bovine serum albumen 
(BSA) in PBS containing 0.05% Tween 20) from immunised and controlled untreated 
animals was added to the wells and incubated for 2 hr at room temperature. The plate 
was again washed and 1:750 dilution of goat antimouse IgG conjugated horseradish 
peroxidase (100 p.1 per well, diluted with of 1% m:v bovine serum albumen (BSA) in 
PBS containing 0.05% Tween 20) added and incubated for 1 hr. Unbound conjugate 
was removed by washing and o-phenylenediamine (0.4 mg/ml in phosphate / citrate 
buffer pH 5.0 containing 0.006% H202, 100 p.l per well) added and the plate 
incubated for 10 min at room temperature. The colouration reaction was stopped by 
addition of 2N HC1 (50 p.1), and the optical density (OD) values were measured at 490 
nm using a Dynatech MR5 000 microplate reader. 
3.12 Binding of anti-ifil and anti-GC1 IgG to peptides 
96-well Costar EIALRIA microtitre plates were coated overnight at 4°C, with serially 
diluted peptide (100 p.Ilwell) in 0.1 M carbonate/bicarbonate buffer pH 9.6. The plate 
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was then washed three times with phosphate buffered saline (PBS) containing 0.05% 
v:v Tween 20. Blocking was achieved by incubating with a solution of 1% m:v bovine 
serum albumen (BSA) in PBS for 1 hr at room temperature. After three further 
washes as described above, either anti-ml IgG, anti-GC1 IgG or IgG from normal 
mouse serum (100 tl per well, diluted with 1% m:v bovine serum albumen (BSA) in 
PBS containing 0.05% Tween 20) was added to the wells and incubated for 2 hr at 
room temperature. The plate was again washed and 1:750 dilution of goat 'antimouse 
IgG conjugated horseradish peroxidase (100 ti per well, diluted with of 1% m:v 
bovine serum albumen (BSA) in PBS containing 0.05% Tween 20) added and 
incubated for 1 hr. Unbound conjugate was removed by washing and o-
phenylenediamine (0.4 mg/ml in phosphate / citrate buffer pH 5.0 containing 0.006% 
H202, 100 d per well) added and the plate incubated for 10 min at room temperature. 
The colouration reaction was stopped by addition of 2N HC1 (50 tl), and the optical 
density (OD) values were measured at 490 nm using a Dynatech MRS 000 microplate 
reader. 
3.13 Protein G purification of antisera 
A column containing Protein G Sepharose 4 fast flow (2g) was washed with 0. 1M 
glycine, pH 2.5 (30m1). The column was then re-equilibrated with 20mM phosphate 
buffer, pH 7 (30m1). The supernatant was then added to the column and the unbound 
protein removed by elution with 20mM phosphate buffer (50m1). The bound IgG was 
then removed from the column with 0. 1M glycine (lOmi), collecting imi fractions. 
Each fraction was dotted onto nitrocellulose and allowed to dry at 37°C. The 
nitrocellulose was stained using coomasie blue (0.25g in lOOml of a solution of 
distilled water containing methanol (10%) and acetic acid (7%)). The fractions 
containing the peptide, appearing on the nitrocellulose as a blue stained central spot, 
were pooled. 
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Chapter 4: Appendices 
4.1 Flow cytometry 
Flow cytometry was carried out on a Coulter EPICS XL Flow Cytometer with a 
15mW, single argon ion laser operating at 488nm. The percentages of labelled cells 
was established relative to background fluorescence of cells treated with fluorescent 
secondary antibody only. 
4.2 Binding of peptides to CD4 +ve cells 
H9 cells, spun over lymphoprep density gradients to remove non-viable cells, were 
suspended in PBS containing 0.5% sodium azide and added to round bottomed 96-
well tissue culture plates at a concentration of 3x 105  cells/well and incubated on ice 
for 2 hr with increasing amounts of peptide in PBS (50 p.!). The cells were washed 
with PBS containing 0.5% sodium azide (50 p.1) and incubated on ice for 1 hr with 
either anti-GC 1 IgG or IgG from normal mouse serum (2 p.g). The cells were washed 
and phycoerythrin conjugated goat anti-mouse IgG added for a fhrther 1 hr on ice. 
The cells were washed and resuspended in PBS containing 0.5% sodium azide for 
reading via flow cytometry. 
4.3 Peptide blocking of anti-CD4 mAb binding to CD4 
Viable CD4 MM6 cells were isolated by gradient centrifugation at 1000 rpm for 25 
mm., washed with PBS (3xlOml) and pelleted in a 96-well microtitre plate at a 
concentration of 10 cells per well. The cells were then incubated on ice for 2 hr with 
IHJ (0.4mM in PBS), washed with PBS and incubated with anti-CD4 niAb (1041, 
100p.g/ml) on ice for 1 hr. The cells were washed with pre-chilled flow buffer (1% 
BSA in PBS with 0.05% w:v sodium azide) and bound mAb detected by incubation 
for 1 hr on ice with phycoerythrin labelled goat anti-mouse immunoglobulin at 1:100 
concentration and counting positive cells by flow cytometly. 
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4.4 Peptide blocking of MLP-la binding to CC-CKR5' cells 
Binding of biotinylated recombinant MIP- la to H9 cells was analysed by flow 
cytometry following the manufacturers protocol, with viable cells being washed in 
PBS (3xlOml) and pelleted in 96-well microtitre plates at a concentration of 10 5 cells 
per well. The cells were incubated with or without peptide in 1% BSA in PBS (lOj.il) 
for 2 hr on ice, treated with biotinylated M1IP- la and detected using FITC labelled 
avidin. Positive cells were then counted using flow cytometry. 
4.5 Localisation of ff1 binding to CD4 cells 
Viable cells were washed in PBS (3xl0ml) and pelleted in 96-well microtitre plates at 
a concentration of 3x10 5 cells per well. The cells were incubated with HE (lpg/weil, 
21 nmol) in binding buffer (1mg/mi GMEM, 10% FCS, 1mg/mi Hepes in water) on 
ice for 2 hr and the plate washed with pre-chilled binding buffer and incubated with 
anti GC 1 polyclonal sera (1:100 concentration in binding buffer) on ice for lhr. The 
cells were washed and any bound anti-GC1 polyclonal sera detected by incubation on 
ice for 30 mm. and at room temperature for 15 mm. with TRITC labelled anti-mouse 
immunoglobulin (1:50 concentration in binding buffer). Cells were washed with pre-
chilled flow buffer (1% BSA in PBS, with 0.05% w:v sodium azide) and biotinylated 
mouse anti human CD4 mAb (clone MT3 10) was added at a concentration of 1:10 in 
flow buffer and incubated on ice for 30 mm. Bound immunoglobulin was detected 
using FITC-labelled avidin at a concentration of 1:100 in flow buffer. Cells were then 
fixed with 0.4% formaldehyde and transferred to slides with a single drop of 
glycerol/PBS. 
4.6 In vitro induction of apoptosis 
a) Solid phase antibody:- Sterile IgG (2p.g/well, lOOp.l) was coated onto tissue culture 
grade, 96-well microtitre plates in 0.05M carbonate/bicarbonate coating buffer, pH 
9.6 overnight at 4 °C. Immediately before use the wells were washed with cold PBS. 
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Cells:- Viable H9 cells passaged in R.PMT containing 3% foetal calf serum 
(3%RPMI) and separated over lymphoprep density gradients were washed with cold 
PBS (2x1OOtl) and counted in 0.5% trypan blue solution. Cells were spun down and 
incubated on ice for 2 hr with PBS (50tl) or PBS containing either 1111 or FMDV 
(50tI, 5g/10 6 cells). The cells were then washed with cold 3%RPML, counted in 
tryphan blue and resuspended at 105iml in 3%RPMI. Quadruplicate sets of 2x10 4 
cells/well were then plated into an IgG coated microtitre plate. The plate was then 
spun gently (100rpm for 3 mm.) and incubated for 5 hr at 37°C in 5% CO2 in a 
humidified incubator. 
Counting apoptotic cells:- After 5 hr incubation at 37°C, contents of the wells were 
made into cytospins, air dried for 10 mm., fixed in acetone for 10 mm. and stained 
with haematoxylin. The percentage of cells showing apoptotic morphology was 
counted by light microscopy. 
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